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Uterine leiomyomas, or fibroids, have a symptomatic incidence of around 40% and are a 
leading cause of reproductive morbidity in reproductively-aged women. Symptoms include 
menorrhagia, pelvic pain, and infertility. They are characterized by excessive production of 
extracellular matrix components, such as collagen. Leiomyomas are responsive to estrogen and 
progesterone and occur more frequently as women age. Risk factors for fibroids include obesity, 
race, localized injury, and stress, while parity has been shown to be protective against fibroids. 
Inflammation has been hypothesized to play a key role in their development. Traditionally, 
hysterectomy or myomectomy has been the treatment for fibroids. However, hysterectomy does 
not preserve a woman’s fertility. Currently, there are no effective long-term, non-surgical 
treatments available for fibroids. Hormone therapies, such as GnRH analogs cannot be used for 
long-term treatment because they induce a state of hypoestrogenism which leads to post-
menopausal symptoms. Researchers have turned to dietary intervention as a possible therapy for 
fibroids because it is non-invasive, safe for long-term use, and relatively inexpensive. Two 
potential candidates for dietary intervention are flaxseed and vitamin D3.  Flaxseed consists of 
two parts: lignan and oil. The lignan portion of flaxseed contains phytoestrogens which may 
inhibit fibroid growth through the antagonism of estrogen. Flaxseed oil is rich in α-linolenic acid, 
which has known anti-inflammatory properties. Vitamin D3 is a hormone involved in calcium 
and bone homeostasis that also possesses anti-inflammatory and anti-fibrotic properties. Because 
the laying hen is the only animal to develop leiomyomas spontaneously as they age, they are an 
ideal animal model for the study of fibroids. Hen leiomyomas occur as polyps on the smooth 




histological and molecular markers as human uterine fibroids including desmin, smooth muscle 
actin, increased collagen, and steroid hormone receptors. 
Two studies were conducted to assess the efficacy of dietary intervention with whole 
flaxseed and vitamin D3. The first study involved feeding White Leghorn hens an isocaloric 
control (basic layer) or 15% whole flaxseed diet ad libitum from the end of their second year of 
lay to the completion of their third. At the end of the study, hens were euthanized and fibroids 
were counted, measured, and collected. Immunohistochemical analyses of fibrosis (Gomori’s 
Trichrome Stain), proliferation (Proliferating Cell Nuclear Antigen), angiogenesis (von 
Willebrand Factor), NF-κB p65, oxidative stress (nitrotyrosine), cellular senescence (Sudan 
Black B), and prevalence of mast cells (Toluidine Blue) were performed on fibroid tissue 
sections. Quantitative RT-PCR was performed to determine changes in expression levels of 
mRNA for collagen I, transforming growth factor-β3 (TGF-β3), and prostaglandin-endoperoxide 
synthase 2 (PTGS2). Western blots were carried out to determine changes in protein levels for 
COX-2. There was a slight decrease in the incidence of leiomyomas in the flaxseed group versus 
the controls. There was no significant difference in the volume of leiomyomas (p=0.3), although 
previous work by our group demonstrated a significant decrease in the size of leiomyomas from 
hens fed a similar diet of 10% whole flaxseed diet for 24 months. Fibroids from hens fed the 
flaxseed-supplemented diet for 12 months showed a modest decrease in proliferation when 
compared to controls and a significant decrease in numbers of blood vessels per unit area of 
fibroid. There were no differences in p65 translocation to the nucleus, a measure of Nuclear 
Factor kappa B (NF-κB) activation, or tissue levels of nitrotyrosine, a measure of oxidative 
stress, between treatment groups. Sudan Black B staining showed that leiomyomas from both 




show mast cell infiltration into fibroids from both groups. Fibroids from hens fed the whole 
flaxseed diet had slightly decreased collagen I (4-fold change, p=0.06) and TGFβ-3 expression 
(6-fold change, p=0.06), while  PTGS2 (6-fold change, p=0.04) expression was significantly 
downregulated when compared to fibroids from hens fed the control diet. COX-2 analysis 
through western blot showed a non-significant decrease in relative COX-2 expression in 
leiomyomas from flaxseed-fed hens compared to those from control hens. 
In the second study, White Leghorn hens having completed their second year of lay were 
fed either an isocaloric control (basic layer), 10% whole flaxseed, or vitamin D3 (69 µg/kg/day) 
diet for 15 months. Twenty-five hens were sacrificed at the start of the trial to determine the 
baseline incidence of leiomyomas. Blood was drawn from the same subset of hens every three 
months until the end of the trial. After 15 months on their respective diets, hens were euthanized. 
Oviducts were collected, and fibroids were counted, measured, and either flash frozen in liquid 
nitrogen or fixed in 10% neutral buffered formalin for further analysis. Leiomyoma incidence 
increased from 44% at the start of the trial to 78%, 74%, and 71% in the control, whole flaxseed, 
and vitamin D groups, respectively after 15 months. The number of leiomyomas per hen in all 
three groups increased significantly after fifteen months when compared to the baseline; there 
were no differences between groups after fifteen months. Plasma carbonylated protein levels 
decreased significantly in the whole flaxseed and vitamin D3-treated hens after 6 months on their 
respective diets; these levels were significantly lower than those of the control hens after 9 
months in both groups. qRT-PCR analysis showed a downregulation of collagen I (50-fold 
change, p=0.02), TGF-β3 (50-fold change, p=0.003), and PTGS2 (100-fold change, p=0.001) 




when compared to those from control hens; there were no differences between the whole 
flaxseed group when compared to the control. 
We conclude that dietary intervention with whole flaxseed or vitamin D3 may have 
beneficial, therapeutic effects on leiomyomas found in the oviduct of the laying hen. Our results 
support further investigation into the use of these supplements in women with fibroids as they 













To my husband: through all of the laughter and tears, you have been there for 
me—comforting me through my darkest hours and celebrating each and every 
victory, no matter how small. I cannot thank you enough for your patience as I 
pursue my goals. You truly bring joy to every aspect of my life. I love you. 
 
To my parents: you have always supported me and taught me the value of hard 
work in achieving my dreams. Words cannot express the love and gratitude I have 
for you. You both are the reason I did not give up and kept pushing forward. 






 I would like to thank everyone that has supported me and provided me guidance 
throughout this entire journey. First and foremost, I want to thank God. Without Him, I would 
not have made it this far in my career. Thank you for always providing me with peace, comfort, 
and joy. Secondly, I would like to extend a huge thank you to Dr. Janice Bahr. If you would not 
have taken the time to talk with me about my future during my senior year, I never would have 
joined Dr. Nowak’s lab, and I definitely never would have applied to grad school. I want to 
extend my biggest thank you to Dr. Romana Nowak for not only the guidance she provided me 
with these past three years, but for also believing in me when I didn’t believe in myself. You 
always gave me that extra push I needed to accomplish my research. Thank you for treating not 
only me, but the entire lab, as part of your family. Next, to Dr. Buck Hales. Thank you for your 
mentorship and willingness to answer my questions, no matter how silly—especially early on in 
my grad school career. (And for driving your team super early on blood draw/sacrifice days!) I’d 
also like to extend a thank you to all of the members of Dr. Hales’ group. Without you guys, we 
never would have accomplished all of our blood draws and tissue collections. To Dr. David 
Miller, thank you for always having an open-door policy and letting me poke my head in with 
random questions any time throughout these past few years. To my lab mates, thank you all for 
being there for every blood draw and tissue collection day throughout my entire chicken study—
especially Cate for being the other bleeder! To Emi, Jalisa, and Megan, thank you for all of the 
RNA and qRT-PCR help—I would not have obtained this data without you. Kadeem, thank you 
for taking over my necropsies when I was unable to make it out to the farm. I could always count 
on you if I needed help with my project or just a friend to talk to. Rebecca, thank you for being 




would also like to extend a thank you to Karen Doty and the Department of Comparative 
Biosciences Core Histology Lab at the College of Veterinary Medicine at the University of 
Illinois at Urbana-Champaign for the Toluidine Blue Staining and for sectioning tissue blocks 
when I was unable to, the Institute of Genomic Biology Core Facilities at the University of 
Illinois for use of the Nanozoomer, Dr. Mark Band and the Roy J. Carver Biotechnology Center 
at the University of Illinois for use of the TaqMan ABI 7900 real time PCR machine and help 
with PCR calculations, Dr. Gregory Freund for use of his lab’s TissueLyser II, Heartland Assays 
for performing the LC/MS-MS analysis, and DSM for kindly donating the Rovimix® for our 
second trial in addition to sponsoring the LC/MS-MS analysis. To Jalisa, you have become one 
of my best friends since joining the MIA project. Thank you for making my transition between 
labs easier, and for calming me when my anxiety gets the best of me. Finally, I’d like to thank 
Dr. Rodney Johnson and Dr. Sandra Rodriguez-Zas for taking a chance and allowing me to lead 
the MIA project even though I hadn’t yet completed my degree. I’ve learned so much in this 
short time, and I hope that you both are proud of the progress we’ve made thus far. I am looking 






TABLE OF CONTENTS 
LIST OF TABLES ...........................................................................................................................x 
LIST OF FIGURES ....................................................................................................................... xi 
INTRODUCTION ...........................................................................................................................1 
CHAPTER 1: LITERATURE REVIEW .........................................................................................2 
CHAPTER 2: WHOLE FLAXSEED SUPPLEMENTATION HAS A POSITIVE, ANTI-
INFLAMMATORY EFFECT ON LEIOMYOMAS IN THE OVIDUCT OF THE LAYING 
HEN ...............................................................................................................................................21 
CHAPTER 3: A DIETARY INTERVENTION STUDY ASSESSING THE EFFECTS OF 
SUPPLEMENTATION WITH 10% WHOLE FLAXSEED OR VITAMIN D3  ON 
OVIDUCTAL LEIOMYOMAS IN THE HEN .............................................................................50 
REFERENCES ..............................................................................................................................70 





LIST OF TABLES 
Table 1: Composition of diets fed in Chapter 2 ............................................................................25 
Table 2: Antibodies used for immunohistochemistry in Chapter 2 ..............................................27 
Table 3: Antibodies used for western blot analysis in Chapter 2 ..................................................32 
Table 4: Composition of diets fed in Chapter 3 ............................................................................53 





LIST OF FIGURES 
Figure 1:  Overview of Prostaglandin Synthesis ..........................................................................13 
Figure 2: Canonical vs. Non-Canonical Activation of NF-κB .....................................................15 
Figure 3: Wound Healing vs. Fibrosis ..........................................................................................16 
Figure 4: Leiomyoma Incidence, Size, and Number per Hen between Control and Whole 
Flaxseed Groups.............................................................................................................................34 
Figure 5: Gomori’s Trichrome Stain for Morphology ..................................................................35 
Figure 6: Proliferating Cell Nuclear Antigen for Proliferation .....................................................36 
Figure 7: Von Willebrand Factor for Angiogenesis .....................................................................36 
Figure 8: NF-κB p65 Nuclear Translocation ................................................................................37 
Figure 9: Nitrotyrosine for Oxidative Stress.................................................................................38 
Figure 10: Sudan Black B for Cellular Senescence ......................................................................39 
Figure 11: Toluidine Blue for Mast Cell Presence .......................................................................39 
Figure 12: Relative Collagen I, TGF-β3, and PTGS2 mRNA Expression between Control and 
Whole Flaxseed Fed Hens .............................................................................................................40 
Figure 13: Relative COX-2/β-Actin Protein Expression ..............................................................41 
Figure 14: 25-hydroxyvitamin D3 Plasma Levels via LC-MS/MS...............................................57 
Figure 15: Leiomyoma Incidence, Size, and Number per Hen between Control, Whole Flaxseed, 
and Vitamin D Groups ...................................................................................................................58 




Figure 17: Comparison of Plasma Protein Carbonyl Content between Treatment Groups ..........60 
Figure 18: Plasma Levels of TNF-α between Treatment Groups .................................................61 
Figure 19: Relative Collagen I, TGF-β3, and PTGS2 mRNA Expression between Control, 






 Uterine leiomyomas, or fibroids, are benign tumors formed from the smooth muscle cells 
of the myometrium. They are characterized by excessive deposition of extracellular matrix 
(ECM) components, such as collagen. Currently, there is little known about the etiology of 
fibroids. Chronic inflammation is hypothesized to play a key role in their development due to its 
interplay with fibrosis. As the most common gynecological tumors in reproductively-aged 
women and the leading cause for hysterectomy in the United States, symptomatic fibroids cause 
pelvic pain, menorrhagia, recurrent pregnancy loss, and infertility. Several risk factors have been 
associated with fibroids including obesity, stress, race, lack of parity, and other genetic and 
environmental factors. Studies have shown the incidence of fibroids to increase with age in pre-
menopausal women while menopause tends to decrease the size of fibroids. These studies 
collectively support the dependence of fibroids on the ovarian steroid hormones estrogen and 
progesterone. Historically, treatment options for fibroids have been very limited and compromise 
a woman’s fertility with hysterectomy and myomectomy being the two most common 
treatments. More recently, gonadotropin-releasing hormone (GnRH) analogs have been used as a 
pharmaceutical treatment for fibroids. However, while successful at decreasing fibroid size, 
GnRH analogs cause hypo-estrogenism and thus, are not approved for long-term use. The 
effectiveness of GnRH analogs is also reversed upon discontinuation of treatment. Because of 
the limited treatments available for fibroids that allow women to preserve their fertility, research 
into dietary intervention therapies has become more popular. The purpose of our studies was to 
determine whether the anti-inflammatory properties of whole flaxseed or vitamin D could be 
exploited as a potential therapy for the treatment of leiomyomas found on the oviduct of the 







Introduction to Uterine Leiomyomas: 
 Uterine leiomyomas are the leading cause of hysterectomy in the United States1 and are 
responsible for up to an estimated 34.37 billion dollars spent annually, both directly and 
indirectly, on women’s healthcare2. Fibroids are benign tumors that form from the smooth 
muscle cells of the myometrium and are dependent upon the ovarian steroid hormones estrogen 
and progesterone3. In order to measure fibroid incidence, Cramer and Patel serially sectioned 100 
uteri at 2-millimeter intervals following total hysterectomy and found that 77 of them contained 
at least one fibroid; this was an incidence significantly higher than fibroids identified upon 
routine pathological examination alone4. Fuldeore and Soliman reported that women with 
symptomatic fibroids suffer from pelvic pain (menstrual and non-menstrual), menorrhagia, 
painful intercourse, and infertility5. They also reported African American women to have an 
increased prevalence of fibroids when compared to Caucasian women, and that prevalence 
increases with age regardless of race5. In fact, by their late forties, 50% of African American 
women have clinically significant fibroids compared with only 35% of Caucasian women6. 
Environmental and genetic factors such as injury, stress, obesity, and race have been shown to 
increase the risk of developing symptomatic fibroids1,7. Despite knowing the incidence, 
symptoms, and risk factors of fibroids, their etiology remains largely unknown although chronic 
local inflammation is hypothesized to play a vital role in their development8. Currently, very few 
treatments for fibroids are available. These range from surgical options, such as 
hysterectomy,myomectomy, and uterine artery embolization, to limited pharmaceutical options, 






Risk Factors and Treatment of Uterine Leiomyomas: 
 Several environmental and genetic risk factors exist for the development of uterine 
leiomyomas, including local injury or infection, stress, obesity, hypertension, race, and parity—
the latter having a protective effect1,7,8,11. Ganesa Wegienka proposed a hypothesis regarding 
how inflammation plays a role in the development of uterine leiomyomas. Briefly, factors such 
as localized injury, infection, stress, and obesity cause the body to be in a chronic, low-grade 
inflammatory state8. If the uterus suffers an insult or multiple insults (i.e., menses), the immune 
response will become pro-inflammatory, leading to smooth muscle cell proliferation and fibrous 
tissue formation8.  
 Obesity, a component of metabolic syndrome, has been linked to uterine 
leiomyomas1,7,12–16. Takeda et al. established the relationship between metabolic syndrome and 
fibroids by showing that patients with increased body mass index (BMI), blood pressure, fasting 
plasma glucose, and hypertriglyceridemia had a higher incidence of symptomatic leiomyomas12. 
A more recent study looking at women with both symptomatic and asymptomatic fibroids had 
similar findings. Tak et al. found that pre-menopausal, parous women with metabolic syndrome 
(increased body fat, waist circumference, blood pressure, and low-density lipoprotein cholesterol 
levels) also had a higher prevalence of leiomyomas13. They also found that metabolic syndrome 
prevalence was greater in women with multiple fibroids than women with just one13. 
 In addition to obesity, hypertension has also been associated with increased risk of 
fibroids11,12,17,18. As mentioned in the previous paragraph, Takeda et al. associated metabolic 
syndrome with an increased risk for leiomyomas12. Another case-control study conducted several 
years earlier studied women with at least one fibroid confirmed by uterine sonogram or 





fibroids and that risk increased from 1.7- to 2.1-fold if the patient was taking anti-hypertensive 
medication11. Luoto et al. performed a cross-sectional study of women undergoing hysterectomy 
and found that 42% of hypertensive women had uterine fibroids compared to only 37% of non-
hypertensive women17. Finally, a prospective study of hypertension and fibroid risk found that 
for every 10-mmHg increase in diastolic blood pressure, the risk for uterine leiomyomas 
increased by 8% for patients not taking anti-hypertensive medication and 10% for those on anti-
hypertensive medication18. The main hypothesis for the association between hypertension and 
increased fibroid risk is that high blood pressure could lead to injury of  smooth muscle cells and 
increase cytokine activity, leading to uterine fibroid development in a process similar to 
atheromatous plaque development11,12,18. Furthermore, atherosclerotic plaque cells and uterine 
leiomyoma cells are both  monoclonal in origin19–21 and behave similarly in culture22. 
 Race has also been shown to be a risk factor for uterine leiomyomas. African American 
women have a 2-3 times greater risk of developing fibroids when compared to Caucasian 
women5,6,23–26. Baird et al. found 30-40% of African American women in their mid- to late-
thirties and 50% in their late forties to have clinically significant leiomyomas compared with 
only 10-15% and 35% of Caucasian women, respectively6. Another study demonstrated the 
heavier burden uterine fibroids pose on African Americans, and their results show that they are 
two times more likely to have abdominal bloating and pressure compared with Caucasian 
women26. Studies also suggest that African Americans are more likely to have other fibrosis-
related diseases, such as keloids, that have an incidence of 15-20%27,28. While the reasons for 
these skewed risks are unclear, data gathered between 2005-2014 show that African American 
women were more likely to be obese than white women29. One study showed a link between 





more likely to have uterine leiomyomas and that the correlation is stronger with a higher BMI 
suggesting that BMI modifies uterine leiomyoma risk in African American women23. It has also 
been shown that serum levels of vitamin D tend to be lower in African Americans than 
Caucasians30,31. Because of the increased likelihood of an African American woman to be both 
obese and deficient in vitamin D, it is possible that more African American women are in a 
chronic pro-inflammatory state and thus, at greater risk for developing fibroids compared to 
white women. In fact, Ciebiera et al. found that patients with higher BMI and serum 
transforming growth factor β3 (TGF-β3) levels, but lower serum vitamin D levels were more 
likely to have uterine leiomyomas than patients with normal BMI, serum TGF-β3, and serum 
vitamin D levels, although this study was conducted with Caucasian women32. 
 Parity, on the other hand, has been shown to lower the risk of uterine leiomyoma 
development33–38. Walker et al. found a significant decrease in leiomyoma incidence in Eker rats 
that had multiple litters compared to those with just one litter34. Another study demonstrated 
significantly decreased relative risk of fibroids with increased number of term pregnancies35. 
Baird and Dunson hypothesize that parity could be protective due to postpartum uterine 
involution38. It is also possible that since a woman is not cycling during pregnancy, there is less 
of a chance for local inflammation at the uterus, thus making parity protective. 
Some genetic factors linked to uterine fibroid development include mutations in the 
mediator complex subunit 12 (MED12) and high mobility group AT-hook 2 (HMGA2) genes. 
MED12 is one of the twenty-six subunits of the Mediator complex39. The Mediator complex 
interacts with RNA polymerase II to regulate the expression of protein-coding genes39. Mӓkinen 
et al. examined a number of uterine leiomyomas and identified that MED12 was mutated in 70% 





human leiomyoma cells in vitro by suppressing Wnt/β-catenin signaling in addition to 
downregulating the expression of cell cycle- and fibrosis-associated proteins41. HMGA2 (also 
known as HMGI-C) is a member of the high mobility group (HMG) family consisting of DNA-
binding proteins which are components of chromatin42. Schoenmakers et al. identified the 
HMGI-C gene on chromosome 12q15 as being consistently altered in various benign 
mesenchymal tumors, including uterine fibroids, suggesting a link between the development of 
benign tumors and the HMG family43. A subsequent study confirmed the role of HMGA2 in the 
development of leiomyomas using the Eker rat model44. They also found that atypical HMGA2 
expression could result from inactivation of the Tsc2 gene (which gives rise to leiomyomas in the 
Eker rat , discussed later), thus providing a link between fibroids found in humans and in the 
Eker rat model44. Targeting the downstream effects of these genetic mutations could provide 
novel, long-term therapies for women suffering from symptomatic fibroids. 
The standard treatment for fibroids used to only include surgical procedures such as 
hysterectomy or open myomectomy9,45–47. Now, a variety of minimally-invasive and non-
surgical treatment options exist that are more advantageous than surgical procedures because 
they preserve women’s fertility. Examples of minimally invasive procedures include vaginal 
myomectomy, fibroid myolysis, magnetic-resonance-guided focused ultrasound surgery 
(MRgFUS), uterine artery embolization (UAE), and laparoscopic uterine artery occlusion 
(LUAO)45. Non-surgical treatment options include hormonal therapies such as GnRH analogs 
and selective progesterone receptor modulators (ulipristal acetate)9,46,48,49. In addition to fertility 
preservation, other advantages of these procedures include less time spent in the hospital, faster 
recovery times, and less time spent off of work. Disadvantages include recurrence of or no 





such as menopause-like symptoms and bone loss. These disadvantages decrease the quality of 
life for women with fibroids. 
Despite the increasing use of these minimally invasive and non-surgical treatment 
options, complications are a common occurrence8,22. When evaluating the efficacy of MRgFUS 
five years post-procedure, Quinn et al. found that while MRgFUS is a safe treatment for 
leiomyomas, it has a high re-intervention rate of approximately sixty percent51. The authors 
hypothesize that this could be due to the percentage of non-perfused volume (NPV) of fibroid 
tissue as they saw a re-intervention rate of fifty percent with MRgFUS treatments that achieved 
at least a fifty percent NPV51. A meta-analysis comparing UAE and LUAO to surgical options 
(hysterectomy or myomectomy) concluded that UAE had increased minor complications, mainly 
persistent symptoms such as menorraghia, when compared to surgical procedures as well as an 
increased chance of surgical re-intervention two to five years later10. They also found that LUAO 
resulted in more cases of persistent symptoms (menorrhagia) along with a higher chance of 
surgical re-intervention within two years of the original procedure10. GnRH analogs, on the other 
hand, are not approved for long-term use in the treatment of leiomyomas because of their 
tendency to induce hypo-estrogenism and postmenopausal symptoms in women who take it9,48,50. 
Because of the lack of effective long-term, non-surgical treatment options, dietary intervention 
therapies might prove to be more successful in treating uterine leiomyomas in the long run. 
Dietary Intervention as a Therapy for Uterine Leiomyomas: 
 Recently, researchers have begun to study the effectiveness of dietary intervention for 
therapeutical treatment of uterine leiomyomas due to the lack of available and effective long-
term treatment options. In vitro studies have shown promising effects for using curcumin in the 





apoptosis, and decreased expression of fibronectin in cultured human leiomyoma cells in a dose-
dependent manner52. The effects of curcumin on proliferation and apoptosis of leiomyoma cells 
were also confirmed by Tsuiji et al. using ELT-3 cells derived from the Eker rat53. Tsuiji et al. 
also found that curcumin exerted its effects on leiomyoma cells through the activation of 
peroxisome proliferator-activated receptor-gamma (PPARγ)53. 
 Genistein, a phytoestrogen and the major isoflavone found in soybeans, has been found to 
inhibit proliferation of leiomyoma cells in vitro54 as well as dysregulate the cell cycle and down-
regulate the TGF-β signaling pathway by decreasing expression of activin A and Smad355. In 
vivo, Sahin et al. found that genistein reduced the size and incidence of spontaneous leiomyomas 
in the oviducts of Japanese quail56. Soy products are becoming popular in many diets, however, 
studies suggest that genistein may have serious effects on women’s reproductive health57–59. For 
example, while genistein has an anti-proliferative effect on leiomyomas, it may also have 
significant negative effects on other parts of the reproductive system. A study conducted by Patel 
et al. used an in vitro follicle culture system to show that genistein inhibits the growth of antral 
follicles through cell cycle inhibition, decreases estradiol levels, alters estradiol precursor 
hormone levels, and dysregulates expression of steroidogenic enzymes57. 
 Other phytochemicals have been identified that have been shown to have anti-
inflammatory, anti-fibrotic, anti-proliferative, and anti-angiogenic properties in various 
biological systems and could potentially be used as a therapy for fibroids60. For example, 
delphinidin, an anthocyanidin found in grapes, pomegranates, and other berries, has been shown 
to suppress proliferation and migration of ovarian clear cell carcinoma cells by downregulating 
the Protein Kinase B (Akt) and Mitogen-Activated Protein Kinases (MAPK) signaling 





muscle actin, fibronectin, and collagen I expression in nasal polyp-derived fibroblasts through 
inhibition of MAPK and NF-κB62. Although not reviewed in this paper by Islam et al., flaxseed 
has been shown to possess anti-inflammatory properties and researchers have begun studying its 
effects as a therapeutical agent for various morbidities such as ovarian cancer and cardiovascular 
disease63–69. With respect to uterine leiomyomas, a case-control study by Atkinson et al. found a 
modest inverse association between uterine fibroid development and urinary excretion of 
enterodiol and enterolactone—two lignan metabolites found in flaxseed70. While more research 
is needed to confirm these findings, flaxseed could prove to be a beneficial dietary intervention 
therapy for uterine fibroids. 
 A lot of promise has been shown in the use of vitamin D as an anti-fibrotic agent71–73. 
Vitamin D is a fat-soluble vitamin that is typically involved in the regulation of calcium 
absorption and bone homeostasis74. It is also known to be involved in the regulation of various 
inflammatory cytokines such as interleukin (IL)-10, IL -1, IL-6, TNF-α, and IFN-γ75–78. Vitamin 
D3, or cholecalciferol, is the form of vitamin D found in most dietary supplements. 
Cholecalciferol (biologically inactive) must be converted to 25-dihydroxyvitamin D in the liver 
prior to its final conversion to 1,25-hydroxyvitamin D, the biologically active form of vitamin D, 
in the kidney74. Dr. Ayman Al-Hendy’s group has contributed much to the study of vitamin D 
and uterine leiomyomas79–86. They first showed that vitamin D inhibited proliferation of human 
leiomyoma cells in vitro suggesting lack of vitamin D to be a risk factor for developing 
fibroids79. Since then, they have also demonstrated that 1,25-hydroxyvitamin D3 reduces 
expression levels of matrix metalloproteinases 2 (MMP-2) and 9 (MMP-9)80, increases the 
expression of vitamin D receptor (VDR)81, and decreases the expression of extracellular matrix 





used as a long-term treatment for fibroids. Finally, an in vivo study conducted by Dr. Al-Hendy 
(using a mouse model injected with ELT-3 cells derived from the Eker rat ) supported using 
paricalcitol, a vitamin D receptor (VDR) activator, given orally, as a new approach in treating 
symptomatic fibroids  since there was significant shrinkage of leiomyomas after treatment with 
paricalcitol82. As can be seen by the numerous studies by Dr. Al-Hendy and colleagues, vitamin 
D possesses great potential to be used as a treatment for uterine fibroids and more in vivo dietary 
intervention studies are needed. 
Animal Models of Uterine Leiomyomas: 
 Animal models have provided a plethora of advancements in the field of medicine, 
largely due to their smaller size and relatively cheap cost. Several animal models for leiomyomas 
are available including the Eker rat, a mouse human leiomyoma-xenograft model, and the laying 
hen.  The most widely used animal model is the Eker rat. The Eker rat carries a mutation in the 
Tsc2 (tuberous sclerosis complex 2) gene that makes it susceptible to tumor formation87. Eker 
and Mossige first observed that this rat strain was predisposed to the development of renal 
adenomas with some tumors resembling carcinomas88. Further characterization of the Eker rat 
mutation has shown a predisposition of these rats to renal cell carcinomas and leiomyosarcomas 
in addition to leiomyomas89. Because of the rarity of leiomyosarcomas in women and their high 
incidence in Eker rats (and renal cell carcinomas), these have been considered to not be truly 
representative of leiomyomas in women. 
Studying human leiomyomas  in vivo is a difficult task to accomplish in women. Mouse 
xenograft models provide a way to perform extensive research on these tumors in vivo without 
the need for establishing clinical trials. (This is not to say that clinical trials are not necessary as 





xenograft models involves taking human leiomyoma cells or fragments of leiomyoma tumors 
and transplanting them into immunodeficient mice under the kidney capsule90,91. The grafted 
leiomyomas retain characteristics of the original tumors when supplemented with estrogen and 
progesterone90. These characteristics include the typical disorganized, whorled appearance of 
smooth muscle cell bundles, collagen deposition, and expression of smooth muscle actin, 
estrogen receptor alpha (ERα), and progesterone receptor (PR) that are found in human uterine 
leiomyomas90,91. Unfortunately, this model also has several  limitations. First: it is expensive, 
second: it depends on having access to fresh human leiomyoma tissues, and third: the success of 
the model depends on the ability of the transplanted human leiomyoma cells to attach, grow, and 
form the tumors. 
Our proposed animal model, the laying hen, develops benign smooth muscle tumors on 
her oviduct without predisposition to malignancies, such as the leiomyosarcoma—unlike the 
Eker rat. Because the laying hen develops these tumors spontaneously, there is no need for 
surgery to implant human leiomyoma cells; thus making the hen a much more cost effective 
model than the mouse xenograft model. As mentioned previously, the laying hen develops 
leiomyomas spontaneously on her oviduct as she ages92,93. Berry et al. demonstrated that like 
those found in women, fibroids from the laying hen express ERα, PR, proliferating cell nuclear 
antigen (PCNA), and the anti-apoptotic protein Bcl-292. Our lab further characterized the laying 
hen as an animal model for human leiomyomas. We found that the incidence of leiomyomas 
increases significantly in the hen after the second year of lay with an overall incidence of 77%, 
similar to women93. The number of fibroids per hen also significantly increases after the second 
year of lay93. Furthermore, leiomyomas in the laying hen were confirmed to possess a smooth 





progesterone receptor and Bcl-2 when compared to the normal smooth muscle cells of the 
oviduct93. In addition, specific-pathogen-free (SPF) hens had virtually no leiomyomas when 
compared to hens housed at the University of Illinois Poultry Research Farm93. This supports the 
idea that infection and inflammation play a role in the development of fibroids. Thus, the laying 
hen as an animal model for human uterine leiomyomas may prove to be a useful tool when used 
in conjunction with in vitro studies and other animal models such as the Eker rat and mouse 
xenograft models. 
Inflammation and Fibrosis: 
 Inflammation is defined as a physiologic immune response of tissue to injury that occurs 
in two phases: the acute phase and the chronic phase94. The acute phase of inflammation is 
characterized by increased blood flow and vascular permeability to the area of tissue damage94. 
Interstitital fluid, leukocytes, and other inflammatory mediators (i.e., cytokines)  accumulate in 
the area during the acute phase94. During the chronic phase of inflammation, humoral and 
cellular responses are mounted that are unique to the pathogens that are present at the site of 
tissue damage94. Chronic inflammatory diseases, such as rheumatoid arthritis, lupus, and 
metabolic syndrome differ from acute infections (i.e., wounds, influenza, etc.) because unlike 
acute infections, the stimuli causing the inflammatory response are  never fully removed95. Two 
pro-inflammatory pathways, and potential targets for uterine fibroid therapy include the 
prostaglandin and nuclear factor kappa B (NF-κB) pathways96–98. 
 Prostaglandin production by cells is regulated by cyclooxygenase enzymes. The 
cyclooxygenase family is made up of two enzymes: cyclooxygenase 1 (COX-1) and 
cyclooxygenase 2 (COX-2)99,100. These enzymes are part of the prostaglandin pathway and are 





constitutively expressed in most tissues at a constant level whereas COX-2 is an inducible 
enzyme that is not present in cells until a specific stimulus occurs100. Most stimuli that induce 
COX-2 expression are pro-inflammatory cytokines while anti-inflammatory cytokines decrease 
COX-2 expression100. 
 Several studies have shown success in down-regulating COX-2 expression as a potential  
treatment for breast, colon, and ovarian cancers both in vitro and in vivo63,101–112. For example,  it 
was found that COX-2 expression was inducible in breast cancer cells in vitro and that treatment 
with American ginseng blocked that expression101. Another breast cancer study investigated the 
potential metastatic effects of sphingosine 1-phosphate (S1P) in vitro and in vivo and found that 
overexpression of the receptor, S1P3, is a potential marker of metastatic breast cancer and that 
S1P upregulates the COX-2/PGE2 pathway in breast cancer105. Using colon cancer as another 
example, one group found that treatment with various culinary herbs and spices (individually and 
in combination) reduced COX-2 expression levels,  inhibited colorectal cancer cell growth, and 
promoted anti-inflammatory effects in vitro107. Jiang et al. examined the effects of retinoic acid 






chalcone (RAC) both in vitro and in vivo on COX-2 expression in colon cancer cells. They found 
that RAC inhibits COX-2 and PGE2 expression and suggested that PGE2 receptors play an 
important role in this inhibition111. A final example of down-regulating COX-2 in cancer is 
found in the treatment of ovarian cancer. One group found that combining calcitriol and the 
COX-2 inhibitor, celecoxib, had an additive effect on the inhibition of COX-2 expression in an 
ovarian cancer cell line suggesting a correlation between vitamin D and prostaglandin 
metabolism in ovarian cancer103. Another study reported  that celecoxib inhibits ovarian cancer 
cell growth in vitro and in vivo under different metabolic conditions through a variety of 
mechanisms related to the inhibition of COX-2104. 
In addition to the prostaglandin pathway, NF-κB is recognized as another major pro-
inflammatory pathway with two distinct mechanisms for activation (Figure 2)113. In the 
canonical activation of NF-κB, pro-inflammatory cytokines such as tumor necrosis factor-alpha 
(TNF-α) or interleukin (IL)-1 bind to their receptors on the cell membrane and activate the IκB-
kinase (IKK) complex consisting of IKKβ, IKKγ, and IKKα. This complex then phosphorylates 
IκB, targeting it for ubiquitination and proteasome degradation, which causes it to release the 
p50/p65 dimer. This dimer then translocates into the nucleus and initiates transcription of 
downstream genes that regulate inflammation and cell survival113. The alternative pathway, on 
the other hand, is activated by cytokines of the TNF superfamily—excluding TNF-α. Ligands, 
such as CD40L and lymphotoxin β, bind to their receptors and activates NF-κB-inducing kinase 
(NIK), thus activating IKKα. IKKα phosphorylates p100, which is broken down into p52 while 





translocated into the nucleus where it binds DNA and facilitates transcription of genes that 
regulate B-cell activation113. 
Down-regulation of the NF-κB signaling pathway has also been shown to be beneficial in 
breast, colon, and ovarian cancer prevention and treatment98,101,112,114–117. In breast cancer, one 
group found that pomegranate emulsion may prevent DMBA-initiated mammary tumorigenesis 
through down-regulation of the NF-κB pathway and up-regulation of the nuclear factor erythroid 
2p45-related factor 2 (Nrf2) pathway (protects against oxidative stress caused by inflammation) 








acids on colitis-associated cancer, found that docosahexaenoic acid (DHA) induced apoptosis of 
human colorectal cancer cells through the inhibition of COX-2 and NF-κB in vitro. This same 
study also found that fat-1 transgenic mice (which possess a gene that encodes for an enzyme 
allowing omega-6 fatty acid to omega-3 fatty acid conversion and therefore contain higher levels 
of omega-3 fatty acids and reduced omega-6 fatty acid levels) had significant protection from 
colitis-associated carcinogenesis through the blocking of β-catenin dissociation, induction of 15-
prostaglandin dehydrogenase, and the repression of COX-2 and NF-κB112. Finally, it was shown 
that melatonin therapy reduced the size and incidence of ovarian cancer tumors in vivo through 
inhibition of the toll-like receptor 4-mediated signaling pathway due to the dampening of 
MyD88 and TRIF signaling pathways, in which NF-κB plays an important role117. 
Figure 3: Wound healing vs. fibrosis. Inflammatory mediators, when unchecked, promote fibrosis through 






In contrast to the various cancers discussed above, leiomyomas are not malignant tumors. 
However, it has been well established that chronic inflammation leads to fibrosis—the central 
event to fibroid development118–121. Figure 3 demonstrates how inflammatory mediators, when 
left unchecked, result in the formation of fibrotic tissue. Normally, after tissue injury, 
inflammatory mediators released from damaged cells initiate rapid healing responses, such as 
blood clot formation, vasodilation, basement membrane disruption, and recruitment of additional 
inflammatory cytokines. Eventually, new cells take the place of damaged ones, and the healing 
process is completed118. When repeated injuries cause chronic inflammation, this healing process 
is disrupted by constant activation of myofibroblasts which ultimately leads to the synthesis of 
excessive ECM118. Myofibroblasts are cells that express smooth muscle proteins, such as actin, 
and are thought to be derived from two sources: differentiation from fibroblasts and through 
epithelial-to-mesenchymal transition (EMT) from epithelial cells118,120.  Several cytokines have 
been implicated in myofibroblast activation, including TNF-α, IL-1β, IL-4, IL-6, the IL-10 
family, IL-13, and TGF-β. 
TGF-β is a key, pro-fibrotic cytokine involved in the development of fibroids and has 
three different isoforms (TGF-β1, TGF-β2, and TGF-β3)122–124. Arici and Sozen found that TGF-
β3 is expressed 3.5 times more in leiomyomas than in the myometrium122. Furthermore, 
fibronectin expression was also increased in leiomyomas compared to the myometrium122. They 
also found that in culture, treatment of leiomyoma cells with TGF-β3 induces fibronectin 
expression in addition to proliferation; TGF-β3 also increased proliferation of myometrial 
cells122. Another study treated myometrial and leiomyoma cells with TGF-β3 and found 
increased mRNA and protein expression of collagen 1A1, fibronectin, and connective tissue 





implicated in the mechanism of action behind TGF-β’s fibrosis-inducing capabilities, however, 
the Smad signaling pathway is arguably one of the most studied pathways in relation to TGF-β. 
Activation of Smad involves TGF-β binding to Smad-coupled receptors. Following ligand 
binding, a heterodimer (Smad2/Smad3) is phosphorylated and becomes activated. These R-
Smads then form a heterotrimer with Smad4. This heterotrimer then translocates to the nucleus 
where it can regulate the transcription of pro-fibrotic genes. 
Anti-Inflammatory Properties of Flaxseed: 
 Flaxseed (Linum usitatissimum) is a cultivated plant that consists of two components: the 
lignan portion and the oil portion. The lignan portion (mainly secoisolariciresinol diglycoside, or 
SDG) acts as a phytoestrogen and may play a role in the prevention and treatment of estrogen-
associated diseases67. Flaxseed oil is rich in α-linolenic acid, an omega-3-fatty acid. Flaxseed has 
been associated with reducing inflammation in a variety of diseases such as type-2 diabetes and 
cardiovascular disease. Jangale et al. showed reduced oxidative stress and down-regulation of 
NF-κB in the kidney of type-2-diabetic mice through dietary intervention with flaxseed oil68. In 
assessing cardiovascular disease risk, α-linolenic acid was found to have a protective effect by 
significantly decreasing C-reactive protein (pro-inflammatory marker) levels as well as 
decreasing lipid and lipoprotein levels69. In addition to its beneficial health effects on type-2 
diabetes and cardiovascular disease, flaxseed has been shown to be beneficial in the treatment of 
several cancers, including ovarian cancer. 
Dr. D.B. Hales’ group at Southern Illinois University School of Medicine has 
demonstrated the protective effects of flaxseed on ovarian cancer in the laying hen model as well 
as elucidated some of the mechanisms by which flaxseed may be exerting its protective 





reduction of PGE2 primarily by inhibition of COX-263,64. Hens fed a flaxseed diet also were 
found to have a down-regulation in Akt and NF-κB signaling pathways as well as altered 
estrogen metabolism. Taken together, these studies have established great potential for the use of 
flaxseed as a therapeutic agent in combating inflammation in various diseases and cancers. 
Anti-Inflammatory/Anti-Fibrotic Properties of Vitamin D: 
 Vitamin D is a fat-soluble vitamin that is important in the regulation of calcium and bone 
homeostasis74. In addition to the aforementioned regulatory functions, vitamin D has also been 
shown to regulate various inflammatory cytokines71,75–78 as well as fibrosis72,73,86. Khoo et al. 
found that vitamin D3 was able to shift the immune response to M. tuberculosis from pro-
inflammatory to anti-inflammatory by reducing TNF-α and IFN-γ production and increasing IL-
10 production75. Another study demonstrated vitamin D’s ability to indirectly inhibit IL-6 
production through the inhibition of TNF-α production125. With regard to vitamin D’s receptor 
(VDR), Zerr et al. found that activation of VDR downregulates TGF-β/Smad signaling and 
concluded that decreased levels of VDR may cause hyperactive TGF-β signaling and fibroblast 
activation in systemic sclerosis72. Vitamin D3 has also been shown to suppress the expression of 
pro-fibrotic genes such as fibronectin, collagen type 1, and PAI-1 through the downregulation of 
TGF-β3 and downstream Smad signaling86. The aforementioned studies provide strong evidence 
to support vitamin D’s anti-inflammatory and anti-fibrotic potential. Therefore, dietary 








 Uterine leiomyomas, or fibroids, are the most common benign, gynecological tumors 
affecting women of reproductive-age. While their etiology remains unknown, inflammation and 
the steroid hormones estrogen and progesterone are hypothesized to play a key role in fibroid 
development and maintenance. Risk factors for leiomyomas include local injury, stress, obesity, 
hypertension, race, and lack of parity. The laying hen has been validated as an animal model for 
fibroids as they develop them spontaneously on their oviduct as they age. Whole flaxseed and 
vitamin D both have been shown to possess anti-inflammatory properties and thus might be 
useful in the prevention and treatment of uterine leiomyomas. Based on the information provided 
in this literature review, the purpose of our studies were to investigate the effects of whole 
flaxseed and vitamin D supplementation as a dietary intervention strategy in the treatment of 







Whole Flaxseed Supplementation has a Positive, Anti-Inflammatory Effect on 
Leiomyomas in the Oviduct of the Laying Hen 
 
Abstract: 
Uterine leiomyomas, or fibroids, are the leading cause of hysterectomies in the United 
States. Fibroids are the most common benign, gynecological tumors in women with the 
incidence of symptomatic fibroids in reproductive-aged women being around 40%.  These 
tumors are known to be a major cause of menorrhagia and also can cause pelvic pain and 
infertility. Leiomyomas are characterized by an overgrowth of extracellular matrix and fibrous 
tissue and are dependent on ovarian steroid hormones for growth and maintenance. Laying hens 
spontaneously develop leiomyomas in their reproductive tract, similar to women.  Leiomyomas 
in hens occur as polyps on the smooth muscle layer of the oviduct with increasing abundance as 
hens age and have the same histological and molecular markers as human uterine fibroids 
including expression of desmin, smooth muscle actin, increased collagen, and steroid hormone 
receptors. Flaxseed has two major biologically active components, oil in the germ and 
phytoestrogen lignans in the hull, thus making it an ideal natural supplement for dietary 
intervention. Flaxseed oil is high in omega-3 fatty acids (alpha-linolenic acid) and these are 
known to act as inhibitors of prostaglandin pathways and as potent anti-inflammatories. Because 
of this, the purpose of our study was to determine whether diet supplementation with flax would 
have a beneficial therapeutic effect on leiomyomas. To assess the effects of whole flaxseed-
supplemented diet versus a control diet, 2.5-year-old hens were fed either an isocaloric control or 
15% whole flaxseed-supplemented diet ad libitum for 12 months. Hens were then euthanized, 





Trichrome Stain), proliferation (Proliferating Cell Nuclear Antigen), angiogenesis (von 
Willebrand Factor), NF-κB p65, oxidative stress (nitrotyrosine), cellular senescence (Sudan 
Black B), and presence of mast cells (Toluidine Blue) were performed on fibroid tissue sections. 
qRT-PCR was performed to determine changes in expression levels of mRNA for collagen I, 
TGF-β3, and PTGS2. Western blot was performed to determine changes in protein levels for 
COX-2. We found that there was a slight decrease in the incidence of leiomyomas in the flaxseed 
group versus the controls. There was no significant difference in the volume of leiomyomas. 
Morphologically, we did not  observe  any differences between fibroids from the two treatment 
groups. Fibroids from hens fed the flaxseed-supplemented diet for 12 months showed a modest 
decrease in proliferation when compared to controls and a significant decrease in numbers of 
blood vessels per unit area of fibroid. There were no differences in p65 expression or in tissue 
nitrotyrosine levels between treatment groups. Sudan Black B staining showed that leiomyomas 
from both groups were not undergoing cellular senescence while Toluidine Blue staining   
confirmed mast cell infiltration into fibroids from both groups. Fibroids from hens fed the whole 
flaxseed diet had modestly decreased collagen I and TGFβ-3 expression, and PTGS2 expression 
was significantly downregulated when compared to fibroids from hens fed the control diet. The 
observed decreases in the number of blood vessels present and mRNA expression level of 
PTGS2 support dietary supplementation with whole flaxseed may have a beneficial impact on 








 Uterine leiomyomas, or fibroids, are the most common benign tumors found in women of 
reproductive age. Formed from smooth muscle cells of the myometrium, fibroids are sensitive to 
estrogen and progesterone3. Approximately 77% of reproductively-aged women have fibroids4, 
and 10-50% of fibroids (depending on race) are clinically significant6. Symptoms of fibroids 
include pelvic pain, menorrhagia, and infertility5. Currently, there are no effective long-term 
treatment options available for leiomyomas. Hysterectomy or myomectomy have traditionally 
been the routine treatment for fibroids causing them to be the leading indication for hysterectomy 
in the United States1. Minimally invasive techniques, such as MRgFUS, provide some relief, but 
have a high surgical re-intervention rate of approximately 60%51. Non-surgical techniques, such 
as the use of GnRH analog therapy reduces the size of fibroids, but induce a state of hypo-
estrogenism, causing women to experience menopausal symptoms48,50. Furthermore, upon 
discontinuation of this therapy, fibroids typically re-grow48,50. Risk factors for development of 
leiomyomas include race, local injury, stress, obesity, and a chronic pro-inflammatory state1,7,8. 
Because there is no effective long-term, non-invasive treatment available for fibroids, the 
purpose of our study is to test the effects of dietary intervention with whole flaxseed as a therapy 
for leiomyomas. Flaxseed consists of two components: the lignan portion, made up of 
phytoestrogens that can potentially  antagonize the action  of estrogen in fibroid development, 
and the oil portion, primarily consisting of α-linolenic acid that has known anti-inflammatory 
properties67. Our previously validated animal model for fibroids, the White Leghorn hen, 
develops leiomyomas spontaneously on the  oviduct with increasing  age93. These benign tumors 





one would see in women93. We hypothesize that dietary intervention with 15% whole flaxseed 
will have beneficial, therapeutic effects on leiomyomas found in the oviduct of the laying hen. 
Materials & Methods: 
Animals: 
White Leghorn hens, aged 2 years and 9 months were randomly divided into groups 
(n=200/group) and fed either a control, 5% corn oil, 5% flaxseed oil, 5% fish oil, 10% defatted 
flaxmeal, or 15% whole flaxseed diet ad libidum for one year. Since corn oil is consists almost 
purely of omega-6-fatty acids, it was used as a negative control against flaxseed oil, which is rich 
in omega-3-fatty acids (specifically, α-linolenic acid). Fish oil served as a control for the type of 
omega-3-fatty acid since it is rich in eicosapentaenoic acid (EPA) and docosahexanoic acid 
(DHA). Table 1 contains the ingredient list and calculated analysis for each of the diets fed. 
Hens were group-housed at the University of Illinois Poultry Research Facility. After one year, 
hens were sacrificed via CO2 asphyxiation and ovaries and oviducts were collected. All animal 
use was approved by the Institutional Animal Care and Use Committee at the University of 





















Corn, % 67.40 52.00 52.00 52.60 54.90 47.58  
SBM, % 18.30 18.30 18.30 18.30 18.30 18.30 
Corn Gluten 
Meal, % 
3.00 5.00 5.00 5.00 0.00 0.00 
Flaxseed 
(whole), % 
0.00 0.00 0.00 0.00 0.00 15.00 
Defatted Flax 
Meal, % 
0.00 0.00 0.00 0.00 10.00 0.00 
Corn Oil, % 0.00 5.00 0.00 0.00 0.00 0.00 
Fish Oil, % 0.00 0.00 5.00 0.00 0.00 0.00 
Flaxseed Oil, 
% 
0.00 0.00 0.00 5.00 0.00 0.00 
Qual Fat, % 0.00 0.00 0.00 0.00 3.80 2.50 
Solka Floc, 
% 
0.30 8.70 8.70 8.70 1.99 5.62 
Limestone, % 8.75 8.75 8.75 8.75 8.75 8.75 
Dical, % 1.50 1.50 1.50 1.50 1.50 1.50 
Salt, % 0.30 0.30 0.30 0.30 0.30 0.30 
Vitamin Mix, 
% 
0.20 0.20 0.20 0.20 0.20 0.20 
Mineral Mix, 
% 
0.15 0.15 0.15 0.15 0.15 0.15 
















CP, % 16.56 16.49 16.49 16.49 17.04 16.50 
TME, kcal/kg 2,816 2,815 2,815 2,815 2,816 2,815 
Calcium, % 3.73 3.73 3.73 3.73 3.77 3.75 
aPhosphorus, 
% 
0.38 0.37 0.37 0.37 0.40 0.38 
Met + Cys, % 0.67 0.67 0.67 0.67 0.72 0.64 






 Upon completion of the study, hens were euthanized, and ovaries and oviducts were 
collected. Leiomyomas found on the oviduct were measured before either being flash frozen in 
liquid nitrogen or fixed in formalin and embedded in paraffin. Because our lab was only 
interested in the effects of whole flaxseed versus a control diet, we only used leiomyomas from 
those two diets for subsequent analyses. Flash frozen leiomyomas were stored at -80⁰C. 
Formalin-fixed, paraffin-embedded leiomyomas were serially sectioned to a thickness of 5µm. 
Sections were floated on lukewarm deionized water prior to being placed on Fisherbrand™ 
Superfrost™ Plus microscope slides (Fisher Scientific, Pittsburgh, PA, USA). Slides were 
allowed to dry overnight on a slide warmer before being used for histological analyses. 
Leiomyoma Incidence and Size: 
 Leiomyoma incidence was calculated by taking the number of hens per treatment group 
that had at least one fibroid, dividing that by the total number of hens per treatment group, and 
multiplying by 100. Data are presented as a percentage. Leiomyoma size was determined by 
measuring fibroids in three dimensions using millimeters as the unit. Volume was calculated 
using the formula V=l x w x h x 0.523, which is the formula for the volume of an ellipsoid and 
has been used to calculate fibroid volume previously127. Data are presented as an average of 
fibroid volume per treatment group. 
Gomori’s Trichrome Stain for Fibrosis: 
Gomori’s one-step trichrome stain was performed in order to evaluate any differences in 
matrix deposition between leiomyomas in the control and whole flaxseed groups. Slides were 





solutions of decreasing concentrations and tap water. Once the deparaffinization and rehydration 
steps were complete, slides were incubated in Bouin’s solution (Sigma-Aldrich, St. Louis, MO, 
USA). Running deionized water was used to wash slides after incubation in Bouin’s solution. 
Slides were then placed in MilliQ water for prior to being placed into Meyer’s hematoxylin. 
After staining in hematoxylin, slides were washed in running tap water and stained in Gomori’s 
trichrome stain (reagents from Sigma-Aldrich, St. Louis, MO, USA and Fisher Scientific, 
Pittsburgh, PA, USA). Following the trichrome stain, slides were dipped in acetic acid prior to 
the dehydration and clearing steps. In order to dehydrate and clear the sections, slides were 
passed through graded ethanol solutions of increasing concentrations and three washes of xylene. 
Finally, slides were mounted with ClearMount™ mounting medium (American MasterTech, 
Lodi, CA, USA). 
Immunohistochemical Analyses for Proliferation, Angiogenesis, NF-κB, and Tissue-Level 
Oxidative Stress: 
Antibody Host Species/Dilution Company 
PCNA (NB500-106) Mouse/1:1000 Novus Biologicals, 
Littletown, CO, USA 
Von Willebrand Factor 
(A008229-5) 
Rabbit/1:400 Agilent Pathology Solutions, 
Santa Clara, CA, USA 
NF-κB p65 
(AB16502) 








Horse/1:100 Vector Laboratories, 
Burlingame, CA, USA 
Biotinylated Anti-Rabbit 
IgG 
Goat/1:100 Vector Laboratories, 
Burlingame, CA, USA 
Table 2: Provides information on antibodies used along with the catalogue number, host species, dilution used, and 






To determine differences in proliferation, angiogenesis, and oxidative stress at the tissue 
level between fibroids from laying hens fed a control diet versus those fed a diet supplemented 
with 15% whole flaxseed, immunohistochemistry was performed for proliferating cell nuclear 
antigen (PCNA), von Willebrand Factor (VWF), NF-κB p65, and nitrotyrosine. Briefly, slides 
were deparaffinized through three washes of xylene and rehydrated through graded ethanol 
solutions of decreasing concentrations and tap water. Next heat-mediated antigen retrieval was 
performed using DAKO Target Retrieval Solution, pH 9 (Agilent Pathology Solutions, Santa 
Clara, CA, USA). Inactivation of exogenous peroxidases was performed by placing slides in 
0.3% hydrogen peroxide/methanol. Blocking of non-specific binding was achieved by incubating 
the slides in 5% normal serum using the host-specific IgG kits from Vector Laboratories 
(Burlingame, CA, USA) diluted in PBST. Primary antibodies were diluted in 1% bovine serum 
albumin (BSA)/PBST (Table 2). Slides were incubated in the primary antibody overnight at 4ᵒC. 
Non-specific IgG (Vector Laboratories, Burlingame, CA, USA) for the appropriate host species 
was used as a negative control on one section of each slide instead of the primary antibody. 
 On the following day, slides were incubated in 1:100 dilution of biotinylated secondary 
antibodies (Table 2) appropriate for each primary antibody’s host species in 1% BSA/PBST. 
Slides were incubated in ABC solution (Vector Laboratories, Burlingame, CA, USA). For 
PCNA, VWF, and NF-κB p65 slides, 3,3’-Diaminobenzidine/peroxidase (DAB) (Vector 
Laboratories, Burlingame, CA, USA) solution was used as a chromogen and then counterstained 
in Mayer’s hematoxylin. Slides were dehydrated through graded ethanol solutions of increasing 
concentrations and cleared through three washes of xylene. Finally, slides were mounted with 
ClearMount™ mounting medium (American MasterTech, Lodi, CA, USA). For nitrotyrosine 





solution incubation. Slides were counterstained in Mayer’s hematoxylin. Because the AEC 
chromogen is soluble in ethanol, slides were mounted with VectaMount™ AQ Aqueous 
Mounting Medium (Vector Laboratories, Burlingame, CA, USA). 
Sudan Black B Stain for Cellular Senescence: 
   When a cell is neither undergoing hypertrophy nor hyperplasia, it is considered 
senescent. Senescent cells are thought to be at the end of their lifecycle, thus, it would be helpful 
to assess this endpoint in testing treatments for fibroids128. In order to assess possible differences 
in cellular senescence between leiomyomas from hens fed a diet supplemented with 15% whole 
flaxseed versus a control diet, Sudan Black B staining was performed. Sudan Black B stains 
lipofuscin granules which have been shown to accumulate in senescent cells129. Briefly, slides 
were deparaffinized and rehydrated through xylene and graded ethanol solutions of decreasing 
concentration. Slides were then incubated in Sudan Black B (Sigma-Aldrich, St. Louis, MO, 
USA) solution at room temperature overnight. The following day, slides were rinsed in 70% 
ethanol until sections were pale grey before being transferred into two washes of ethanol. Slides 
were then cleared and mounted with ClearMount™ mounting medium (American MasterTech, 
Lodi, CA, USA). 
Toluidine Blue Stain to Assess Presence of Mast Cells: 
 To determine any differences in mast cell infiltration in leiomyoma tissue between 
treatment groups, leiomyomas were sectioned to a thickness of 5 micrometers and then stained 
with Toluidine Blue. The Core Histology Lab in the Department of Comparative Biosciences at 





 Sections were deparaffinized and hydrated through graded alcohol solutions to water. 
Slides were stained in 0.1% Aqueous Toluidine Blue solution for 10 minutes followed by rinsing 
in distilled water. Dehydration of sections occurred quickly through 95% and 100% alcohol. As 
this step differentiates the stain, slides were checked carefully throughout this process. Finally, 
slides were cleared through xylene and mounted. 
RNA Isolation and cDNA synthesis: 
 RNA was isolated from fibroids using the Trizol method. Briefly, 50-100 mg of tissue 
were homogenized in 1 mL of Trizol using 2mm Tungsten Carbide beads and the TissueLyserII 
both from Qiagen. Fibroids were macerated for 25 second intervals with 5 seconds on ice 
between intervals. Following homogenization, 200 µL of chloroform were added to sample 
tubes. Tubes were vortexed and incubated at room temperature for 10 minutes. Following 
incubation, tubes were centrifuged at 12,000xg for 15 minutes at 4⁰C in a microcentrifuge. After 
centrifugation, the aqueous layer was extracted. 500 µL of isopropanol and 5 µL of glycogen (for 
pellet visualization) were added to the aqueous layer and samples were vortexed and incubated 
overnight at -20⁰C. The following day, samples were centrifuged at 12,000xg for 15 minutes at 
4⁰C in a microcentrifuge and the supernatants were discarded. Pellets were washed with 75% 
ethanol and centrifuged at 12,000xg for 5 minutes at 4⁰C. Supernatants were again discarded and 
pellets were allowed to air dry. Finally, pellets were re-suspended in 22 µL of nuclease free 
water. A260/280, A260/230, and RNA concentration were measured using the Nanodrop. cDNA 
was synthesized from RNA samples using the High Capacity cDNA Reverse Transcription Kit 







 Quantitative reverse transcription PCR was performed using a TaqMan ABI 7900 real 
time PCR machine at the Roy J. Carver Biotechnology Center at the University of Illinois at 
Urbana-Champaign. Changes in mRNA levels of collagen I (Gg03325897_m1), TGF-β3 
(Gg03371523_m1), and PTGS2 (Gg03320004_m1) from leiomyomas found in hens fed either 
the control or whole flaxseed-supplemented diet were measured. 18S (Hs99999901_s1) was used 
as the housekeeping gene. All primer probe sets were purchased from Applied Biosystems 
(TaqMan™, Foster City, CA, USA). Statistical analysis was performed on delta Ct values. Data 
are presented as relative fold change. 
It is important to note that due to high variation in our housekeeping gene between 
samples, our relative fold change average of our control samples was not equal to 1. Therefore, 
we divided our control and flaxseed fold change averages by the average fold change value of 
the controls to accurately depict relative fold change in our graphs. Statistical analyses were not 
performed on these values as they induced artificial significance. 
Protein Isolation: 
NP-40 lysis buffer was used to isolate proteins from fibroids using the following 
protocol: approximately 50 mg of tissue were placed into 2 mL of lysis buffer. Using the 
TissueLyserII and 2mm Tungsten Carbide beads from Qiagen, fibroids were homogenized for 25 
seconds followed by 5 seconds on wet ice. This step was repeated as necessary until fibroids 
were completely disrupted. Following homogenization, samples were centrifuged at 12,000xg 
for 10 minutes at 4⁰C. The supernatant was divided into aliquots and stored at -80⁰C until needed 






Antibody Host Species/Dilution Company 
COX-2 
(160126) 
Rabbit/1:1000 Cayman Chemicals, Ann 
Arbor, MI, USA 
Β-Actin 
(A5060) 





Goat/1:5000 Cell Signaling Technology, 
Danvers, MA, USA 
Table 3: Antibodies used for western blot analysis along with their catalogue number, host species, dilution used, 
and company purchased from. 
 
 Protein samples were thawed on wet ice and concentration was determined using the 
Pierce™ BCA Protein Assay Kit (ThermoFisher Scientific, Waltham, MA, USA) prior to 
performing the western blot protocol. Gels were loaded with 15 mg of protein along with 4xLSB 
(3 parts protein to 1 part 4xLSB). BioRad protein ladder was used for the standards. The gels 
were run at 120V for 1 hour and then transferred to PVDF membranes (100V for 1 hour). 
Membranes were blocked in 3% BSA/TBST overnight at 4⁰C on a shaker. The following day, 
the blocking solution was discarded and primary antibody for COX-2 was applied. Membranes 
were incubated in the primary antibody overnight at 4⁰C on a shaker (Table 3). On the third day, 
membranes were washed three times in TBST for 10 minutes prior to being incubated in the 
secondary antibody for 1 hour at room temperature on a plate shaker (Table 3). Following 
another three washes in TBST, membranes were incubated in SuperSignal™ West Pico PLUS 
Chemiluminescent Substrate (ThermoFisher Scientific, Waltham, MA, USA) for 5 minutes in the 
dark and visualized using an ImageQuant machine. Once imaging was complete, membranes 
were stripped for 15 minutes at room temperature on a plate shaker with Restore™ Western Blot 
Stripping Buffer (ThermoFisher Scientific, Waltham, MA, USA). Membranes were again 





solution was discarded and primary antibody for the loading control (β-actin) was applied. 
Membranes were incubated in the primary antibody overnight at 4⁰C on a shaker (Table 3). On 
the final day, membranes were washed three times in TBST for 10 minutes prior to being 
incubated in the secondary antibody for 1 hour at room temperature on a plate shaker (Table 3). 
Following another three washes in TBST, membranes were incubated in SuperSignal™ West 
Pico PLUS Chemiluminescent Substrate (ThermoFisher Scientific, Waltham, MA, USA) for 5 
minutes in the dark and visualized using an ImageQuant machine. 
Nanozoomer Analyses: 
 All slides were scanned on the Nanozoomer Slide Scanner at the Institute for Genomic 
Biology Core Facilities at the University of Illinois at Urbana-Champaign and analyzed using the 
Nanozoomer software. For PCNA quantification, positive cells were counted in 10 high-power 
fields from 3 sections per sample and averaged together. Using the Nanozoomer software, the 
area of each high-power field was calculated and data are represented as number of positive cells 
per millimeter squared. Quantification of Von Willebrand Factor was similar, except all blood 
vessels were counted and the area of each fibroid section was calculated. Data are represented as 
number of blood vessels per millimeter squared. Finally, NF-κB p65 was quantified using the 
same method as for PCNA. Only cells with positive nuclear staining for p65 were counted as 
they were indicative of active NF-κB signaling. 
Statistical Analyses: 
 All statistical analyses were computed using GraphPad Prism 7.0. The D’Agonstino and 







Leiomyoma Incidence, Number of Leiomyomas per Hen, and Size: 
After one year on either the control or 15% whole flaxseed-supplemented diet, we found 
that hens had an incidence of leiomyomas of 44.44% and 33.02%, respectively (Figure 4A). The 
average number of fibroids per hen were 1.25 for those fed the control diet and 1.2 for those fed 
the 15% whole flaxseed diet (Figure 4B). To calculate volume, leiomyomas were measured in 3 
dimensions, and the formula V = l x w x h x 0.523 was used. The average size of leiomyomas 
from the control group was 148.3 mm3 (n=227) and the average for the flaxseed group was 96.62 
mm3 (n=197). There were no statistically significant changes in the average volume of 
leiomyomas in either group (p=0.31), although there appears to be a modest decrease in those 
from hens fed the whole flaxseed diet (Figure 4C). 
  
Figure 4: Incidence, number, and size of leiomyomas. A) After one year on their respective diets, incidences of 
fibroids were ~44% for control hens and ~33% for those fed the flaxseed diet. B) There were no differences in the 
number of fibroids per hen in either treatment group (control n=126, flaxseed n=106, p=0.10). C) There were no 





Morphology and Fibrosis: 
 We were interested in determining whether fibroids from hens fed a whole flaxseed-
supplemented diet contained a lower amount of collagen than those from control hens. Gomori’s 
trichrome stain was performed to assess collagen deposition. Figure 5 shows a representative 
example of a fibroid from a hen fed a control diet and one from a hen fed a diet supplemented 
with whole flaxseed. The pink depicts smooth muscle cells while the blue represents collagen. 
We did not detect any differences in ECM deposition between control (n=18) and whole flaxseed 
(n=16) fibroids. 
Proliferation: 
 Cellular proliferation plays an important role in tumor growth and survival. Thus, we 
next wanted to investigate whether whole flaxseed fibroids had decreased proliferation compared 
to the controls. Immunohistochemistry was performed and an antibody for PCNA was used. 
Fibroids from hens fed the whole flaxseed diet (n=22) had a trending decrease in the number of 
proliferating cells when compared to fibroids from control (n=21) hens (p=0.06, Figure 6). 
Figure 5: Representative Gomori's Trichrome Stain. Pink represents smooth muscle cells. Blue depicts collagen 
deposition. A) Leiomyoma from hen fed the control diet (n=18). B) Leiomyoma from hen fed the 15% whole 






 To assess differences in blood vessel formation in fibroids from hens fed either the 
control or flaxseed-supplemented diet, we immune-stained fibroid sections with an antibody 
against von Willebrand factor—a known marker of endothelial cells. We found that fibroids 
from hens fed a diet supplemented with whole flaxseed (n=14) had significantly fewer blood 
vessels when compared with those from hens on the control diet (n=14, p=0.02, Figure 7). 
  
Figure 6: Proliferating Cell Nuclear Antigen. Examples of positive cells in leiomyomas from hens fed A) the 
control diet (n=21) and B) the 15% whole flaxseed diet (n=22). C) Quantification of the average number of 
positive cells per square millimeter in leiomyomas. There was a modest decrease in the number of proliferating 
cells from hens fed the 15% whole flaxseed diet (p=0.06). 
Figure 7: Von Willebrand Factor. Representative examples of blood vessels in leiomyomas from hens fed A) the 
control diet (n=14) and B) the 15% whole flaxseed diet (n=14). C) Quantification of number of blood vessels per 
square millimeter in leiomyomas. Fibroids from hens fed the flaxseed diet had significantly fewer blood vessels 





Nuclear Factor kappa B: 
 NF-κB is a well-known pro-inflammatory signaling pathway. In the classical activation 
of this pathway, IκB is phosphorylated causing release of the p50/p65 dimer and its subsequent 
translocation into the nucleus, thus rendering the pathway active. Immunohistochemical staining 
against p65 was performed to determine the localization of p65 in fibroids from hens fed either 
the control (n=12) or whole flaxseed (n=15) diets. Cells with active NF-κB signaling express p65 
in the nucleus and were counted. 10 high-power-fields from each fibroid were averaged together 
to determine the average number of nuclear-positive p65 cells per square millimeter. We found 
no differences in cells expressing active NF-κB signaling between groups (p=0.86, Figure 8). 
Measure of Oxidative Stress in Tissue: 
Immunohistochemical staining for nitrotyrosine was performed to assess oxidative stress 
at the tissue level. Fibroids from hens in both the control (n=12) and whole flaxseed (n=17) 
groups showed a generalized staining for nitrotyrosine throughout the entire tumor sections 
(Figure 9A-B, D-E). However, we noticed that in samples that had some oviduct still attached to 
the fibroid, the oviduct showed virtually no nitrotyrosine staining (Figure 9C,F). Therefore, we 
Figure 8: NF-κB p65 localization. Black arrows depict nuclear staining of p65 and active NF-κB signaling. Red 
arrows depict cytoplasmic staining of p65 and no active NF-κB signaling. A) Example of a fibroid from a hen fed 
the control diet (n=12). B) Example of a fibroid from a hen fed the 15% whole flaxseed diet (n=15). C) 





decided to stain control oviduct samples in addition to the fibroids. As can be seen in Figure 9G-
I, nitrotyrosine was localized to the smooth muscle cells and glandular epithelium in the oviduct. 
  
Figure 9: Nitrotyrosine. A) Overview of a fibroid from a hen fed the control diet (n=12). B) 20X view of the 
control fibroid (n=17). C) 20X view of the oviduct tissue attached to the control fibroid. D) Overview of a 
fibroids from a hen fed the whole flaxseed diet. E) 20X view of the flax fibroid. F) 20X view of the oviduct 
tissue attached to the flax fibroid. G) Overview of an oviduct section taken from a control hen. H) 20X view of 
smooth muscle cells of the oviduct. I) 20X view of glandular epithelium and surrounding stroma of the oviduct. 






 Sudan Black B staining was performed to determine levels of senescence, if any, in our 
fibroid samples. We found that neither leiomyomas from hens fed the control diet (n=14) nor 
those from hens fed the whole flaxseed diet (n=15) contained any senescent cells, as can be seen 
in Figure 10B-C. Human endometrium was stained as a positive control (Figure 10A). 
Presence of Mast Cells: 
Infiltration of immune cells, such as mast cells, is an important part of the inflammatory 
response. To determine whether mast cells were infiltrating into leiomyomas, toluidine blue 
staining was performed. We found mast cells present in fibroids from both control (n=19) and 
whole flaxseed treated hens (n=23). The majority of mast cells were found near the edges of 
leiomyomas as well as near blood vessels (Figure 11). 
Figure 10: Sudan Black B Stain for Cellular Senescence. A) Human endometrium used as a positive control. The 
black stain represents the lipofuscin granules. B) Fibroid from hen fed the control diet (n=14). C) Fibroid from 
hen fed the diet supplemented with whole flaxseed (n=15). 
Figure 11: Toluidine Blue stain. Mast cells are stained deep blue (depicted by arrows). A) Mouse spleen used 
as a positive control. B) Fibroid from hen fed the control diet. C) Fibroid from hen fed the whole flaxseed diet. 
While mast cells appear throughout the fibroids, they were most commonly seen around the edges of fibroids 






 Collagen I, TGFβ-3, and PTGS2 expression levels were measured relative to the 
housekeeping gene, 18S, in leiomyomas from hens in each treatment group (control n=15, whole 
flaxseed n=14). We found that both collagen I and TGFβ-3 were downregulated in fibroids from 
hens fed the whole flaxseed diet, but this downregulation was not significant (Figure 12A-B). 
Leiomyomas from whole flaxseed-fed hens, on the other hand, did have a significant 
downregulation of the PTGS2 gene (p=0.04, Figure 12C). 
Western Blot: 
 Western blot analysis for COX-2 was performed relative to β-actin to assess protein 
expression levels in leiomyomas from control-fed hens (n=9) and flaxseed-fed hens (n=9). COX-
2 exists in two isoforms in the chicken, and we were able to detect both of them in our samples 
(Figure 13A). While both the higher and lower molecular weight bands show a decrease in 
Figure 12: Relative Collagen I, TGFβ-3, and PTGS2 Expression. A&B) Fibroids from the whole flaxseed group 
showed a trending decrease of collagen I and TGFβ-3 mRNA expression when compared to those from the control 
group. C) PTGS2 was downregulated six-fold in fibroids from hens on the flaxseed diet when compared to those 





COX-2 expression in fibroids in the whole flaxseed group, neither of these changes are 
significant (p=0.17 and p=0.23, respectively, Figure 13B-C). 
Discussion: 
 Currently, there are no effective long-term, non-surgical options for the treatment of 
uterine leiomyomas. The purpose of this study was to test the efficacy of dietary intervention 
with 15% whole flaxseed on leiomyomas by feeding White Leghorn hens either a control or 15% 
whole flaxseed-supplemented diet for 12 months. Overall, we found a modest decrease in 
proliferation in fibroids from hens fed the whole flaxseed diet compared to those fed the control 
diet. Our data also show fibroids from hens fed the flaxseed diet had significantly fewer blood 
 
Figure 13: COX-2 protein expression relative to β-actin. A) Two isoforms of COX-2 were detected with 
molecular weights of ~75kDa and ~50kDa. B) Quantification of the isoform around 75kDa. Control n=9, 






vessels per unit area than those from control hens. Finally, we demonstrated a modest decrease in 
collagen I and TGF-β3 gene expression and a significant decrease in PTGS2 gene expression. 
 There were no differences in the number of fibroids per hen or the size of fibroids from 
hens fed either the control diet or the 15% whole flaxseed diet for 12 months. Based on the 
results of a previously conducted study by our group which demonstrated a significant decrease 
in the number of fibroids per hen and the size of leiomyomas from hens fed a similar diet 
consisting of 10% whole flaxseed for 18-24 months (data unpublished), there appears to be an 
effect of the length of time treatment is administered. Because hens in the previous study were 
fed this diet for twice the amount of time as our hens, we suspect that a longer period of time is 
required to see fibroid shrinkage with whole flaxseed supplementation. Furthermore, we 
witnessed a decreased incidence of fibroids in hens on the flaxseed diet after 12 months 
compared to the controls. The remainder of our findings suggest that molecular processes are 
occurring after 12 months that lead to the changes seen in leiomyomas after 18-24 months of 
dietary intervention with whole flaxseed. 
 Leiomyomas from hens fed the flaxseed diet had fewer proliferating cells than did those 
from hens on the control diet. Our results are consistent with various cancer studies that reported 
that flaxseed treatment decreases the number of proliferating cells in tumors130–132. In a study 
assessing the efficacy of flaxseed as a preventative for ovarian cancer, Dikshit et al. did not 
observe a decrease in cell proliferation within normal ovaries from hens fed a 5%, 10%, or 15% 
whole flaxseed diet compared to those fed a control diet65. However, unlike cancerous tumors, 
fibroids are not highly proliferative, and a decrease in cell proliferation within fibroids in the 





Nitrotyrosine is a general marker of nitrative stress, a form of oxidative stress133. Mast 
cells are granulocytes that release histamine and other factors during the inflammatory response. 
Oxidative stress and infiltration of mast cells were evaluated histologically in fibroids from both 
the control and whole flaxseed treatment groups. Fibroids from both groups exhibited 
generalized nitrotyrosine staining and infiltration of mast cells near tumor edges and blood 
vessels. Furthermore, nitrotyrosine staining was elevated in fibroids compared to normal oviduct 
tissue. These results are indicative of the occurrence of inflammatory responses in leiomyomas, 
supportive of the hypothesis that fibroids are caused, in part, by a chronic, pro-inflammatory 
state8. Consistent with our finding of elevated oxidative stress levels in leiomyomas versus 
normal oviduct tissue, Fletcher et al. investigated oxidative stress in vitro in cultured leiomyoma 
cells compared to cultured myometrial cells and found that myeloperoxidase, inducible nitric 
oxide synthase, and total nitrate and nitrite concentrations were increased in leiomyoma cells 
compared to myometrial cells134. Furthermore, this same group demonstrated upregulated 
nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4), a source of oxidative stress, in 
leiomyoma cells and tissues compared to normal myometrium135. Nitrotyrosine is only one 
indicator of oxidative stress, and further investigation into other markers (in addition to 
nitrotyrosine) could lead to new therapies for uterine fibroids that target oxidative stress 
pathways. 
Cellular senescence is a state of growth arrest that can be indicative of the end of a cell’s 
lifecycle. One study demonstrated induction of cellular senescence in three-dimensional 
leiomyoma cell cultures following Akt inhibition128. Because the fibroids we collected from our 
hens were formalin-fixed and embedded in paraffin, we decided to perform Sudan Black B 





diet exhibited any Sudan Black B uptake, indicating that none of the fibroids we collected were 
undergoing senescence. Leiomyomas are common throughout the reproductive years of women, 
often regressing during menopause. This means that a woman could have a fibroid for a number 
of years, much longer than the hens on our study had them. It is possible that the tumors found in 
our hens were not ‘aged’ enough to be undergoing cellular senescence and therefore their cells 
are not near the end of their lifecycles. However, further studies are needed with our animal 
model to assess whether or not flaxseed could play a role in inducing senescence in leiomyomas. 
 Angiogenesis, the development of new blood vessels, is an important process for tumor 
survival and growth. Chronic inflammation causes increased endothelial cell activation, leading 
to angiogenesis136. Zanetta et al. demonstrated upregulation of von Willebrand Factor mRNA 
and protein levels by VEGF and FGF-2 in cultured human endothelial cells along with frozen 
human colon carcinoma tissues and normal colon tissue from patients undergoing a colon 
resection, suggesting VWF as a useful marker for endothelial cell activation and angiogenesis137. 
Immunohistochemical staining in our study for von Willebrand Factor showed significantly 
fewer blood vessels in fibroids from flax-fed hens compared to those from control hens. This 
result demonstrates the potential anti-inflammatory benefits of flaxseed on leiomyomas through 
the decrease of endothelial cell activation and angiogenesis. A study investigating the effects of 
diets high in polyunsaturated fatty acids and α-linolenic acid on cardiovascular disease risk found 
that a diet high in α-linolenic acid significantly reduced serum levels of C-reactive protein, 
intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin in men 
and women with high cholesterol69. They concluded that dietary α-linolenic acid  exhibited 





alongside ours, support the anti-inflammatory properties of α-linolenic acid on endothelial cell 
activation. 
 In order to further investigate mechanisms through which flaxseed could exert its effects 
on leiomyomas in the laying hen, immunohistochemistry was performed to assess the 
translocation of p65 to the nucleus of fibroid smooth muscle cells, which would be indicative of 
NF-κB activation—a major pro-inflammatory pathway. We found no differences in the levels of 
p65 translocation between fibroids from hens fed either the control or 15% whole flaxseed diet, 
suggesting that suppressing NF-κB is not the main pathway by which flaxseed exerts its anti-
inflammatory effects. In agreement with our finding, Heymach et al. showed NF-κB 
downregulation in men with prostate cancer consuming a low-fat diet versus those consuming a 
flaxseed-supplemented diet138. Another study found that whole flaxseed downregulated nuclear 
receptor coactivator 1 (NCOA1) mRNA expression, a NF-κB regulator, in the ovaries of White 
Leghorn hens, but had no effect on NF-κB mRNA expression66. They proposed that the flaxseed 
diet might regulate  NF-κB activation by preventing nuclear translocation of NF-κB’s 
transcriptional units66. However, our results show that this is not the case with regard to fibroids 
from hens fed a whole flaxseed-supplemented diet. Worthy of note, immunohistochemistry is 
generally recognized as a subjective and semi-quantitative analysis because it is up to the viewer 
to determine immunoreactive cells and the sections being analyzed are only microns thick 
compared to the actual size of the tissue. In an attempt to minimize error and ensure our results 
are representative of each sample, an average of ten high power fields per section and three 
sections per fibroids were counted. Samples were also analyzed blindly. However, it is possible 
that by not counting every nuclear-positive cell in the entire fibroid differences in NF-κB 





technique. Assessment of other effectors of the NF-κB pathway, such as NCOA1 mentioned 
above, through more quantitative methods could solidify our results. 
 We next investigated the effects of whole flaxseed supplementation on mRNA expression 
of three genes well-known to play a role in fibroid biology: collagen I, TGF-β3, and PTGS2. 
Collagen is a main component of ECM and TGF-β3 is a pro-fibrotic cytokine whose mRNA is 
expressed at higher levels in leiomyomas than normal myometrium and has been shown to 
induce fibronectin expression in leiomyoma cells122.  TGF-β3 also increases the production of 
collagen I124. Previously, Machado et al. showed that leiomyomas from the laying hen expressed 
higher levels of collagen I and TGF-β3 compared to normal oviduct93. Collagen I and TGF-β3 
mRNA expression were modestly decreased in fibroids from hens fed the whole flaxseed diet 
compared with those hens fed the control diet. These results suggest that flaxseed is having a 
beneficial effect on leiomyomas, however, consumption of the whole flaxseed diet over a longer 
period of time could lead to greater reductions. Future studies are needed to determine whether 
this is the case. 
 Fibroids from hens fed the 15% whole flaxseed diet showed a significant decrease in 
PTGS2 mRNA expression compared to those from hens fed the control diet. PTGS2 is the gene 
that codes for COX-2, the inducible enzyme in the prostaglandin pathway. The COX-
2/prostaglandin pathway is implicated in a variety of inflammatory diseases, including cancer, 
and downregulating this pathway has been shown to be potentially beneficial to hinder disease 
progression63–65,97,105. Dr. D.B. Hales’ group has extensively studied the effects of flaxseed 
supplementation on ovarian cancer in White Leghorn hens. According to their research, flaxseed 
reduces the severity of ovarian cancer by inhibiting COX-2 and subsequent PGE2 production in 





dietary flaxseed through decreased PTGS2 expression, which could have a beneficial, therapeutic 
effect on fibroids. 
It is important to note that our housekeeping gene didn’t run as expected in that it there 
was a lot of variation between samples. There are a few possible reasons for this. First, it is 
possible that 18S isn’t the best housekeeping gene for our samples and species. However, 
previous work with leiomyomas in the laying hen from our lab used 18S as a housekeeping gene 
successfully, so this is unlikely the case93. Second, our extracted RNA was analyzed on a 
Nanodrop Spectrophotometer prior to cDNA synthesis and were not treated with DNase. 
Because the Nanodrop cannot differentiate between RNA and DNA, it is possible that the 
amplification we witnessed was DNA amplification and not mRNA amplification. Our 18S 
primer-probe was designed within a single exon whereas our collagen I, TGFβ-3, and PTGS2 
primer-probes were designed across an exon junction, thus making DNA contamination and 
amplification in our housekeeping samples probable. 
 Western blot analysis showed a slight decrease in both isoforms of COX-2’s expression 
relative to the β-actin loading control. As mentioned previously, COX-2 is the rate-limiting 
enzyme in the prostaglandin pathway and plays a role in various inflammatory diseases. Ke et al. 
investigated COX-2 expression in uterine leiomyomas in comparison with normal uterine tissue 
from women undergoing laparoscopy for their fibroids and found increased COX-2 expression in 
leiomyomas, suggesting an important role of COX-2 in uterine fibroids pathogenesis139. A 
different study simulated a menstruation-like environment by adding PGE2 to cultured 
leiomyomas cells140. Their results demonstrate that PGE2 increased COX-2 expression compared 
to non-treated cells140. Furthermore, they demonstrate that celecoxib (a COX-2 inhibitor) 





suggesting that celecoxib could inhibit leiomyoma growth140. In agreement with the 
aforementioned in vitro study, we saw a modest decrease in proliferation of our leiomyomas in 
the flaxseed group and a slight decrease in COX-2 expression in vivo, suggesting that flaxseed 
supplementation could be working to inhibit fibroid growth through the inhibition of COX-2. 
Furthermore, our western blot analysis agrees with our qRT-PCR analysis of PTGS2, the gene 
that codes for COX-2. While the changes in COX-2 expression were not significant, we suspect 
that a longer time on the 15% whole flaxseed diet will lead to a significant reduction in COX-2 
protein expression and overall leiomyoma growth. 
Conclusions and Future Directions: 
 Altogether, we conclude dietary intervention with whole flaxseed has therapeutic, anti-
inflammatory effects on leiomyomas found in the oviduct of the laying hen, but the length of 
time in which the flaxseed diet is consumed plays a role in its ultimate efficacy. While our results 
depict an elementary peek into the mechanisms behind which flaxseed exerts its effects, a lot of 
future work needs to be completed to further elucidate these mechanisms and strengthen our 
findings. For example, assessing mRNA and protein expression of end products in the 
prostaglandin pathway, such as PGE2 or PGF2α, between fibroids from control and flaxseed-fed 
hens would be valuable in determining if the prostaglandin pathway is a target of dietary 
flaxseed in the scope of leiomyoma treatment. Other valuable endpoints to assess in the 
elucidation of the mechanism of action behind dietary flaxseed would be mRNA and protein 
levels of inflammatory cytokines, such as IL-1β (pro), IL-6 (pro), and IL-10 (anti) in leiomyomas 
found in hens from each diet. 
 As mentioned in our discussion, our 18S housekeeping gene did not run properly during 





to repeating this experiment. First, isolated RNA should be treated with DNase to digest any 
DNA in the sample. Secondly, more thorough quality control of our RNA should be conducted 
prior to running qRT-PCR, such as analysis using an Agilent Bioanalyzer machine. Third, a 
housekeeping gene designed across an exon junction would minimize the risk of DNA 
contamination in our samples interfering with the true results of the qRT-PCR experiment. Our 
18S primer-probe was a Taqman assay from Applied Biosystems and was designed to target 
human 18S. Because of previous results from our lab with this specific primer in chicken 
samples, we chose to use this assay again. However, there is a GAPDH Taqman assay available 
that is designed for the chicken as a target species in addition to spanning an exon junction. 
 In addition to assessing the efficacy of dietary intervention with whole flaxseed as a 
therapy for leiomyomas, it would be interesting to test dietary intervention with whole flaxseed 
as a preventative for fibroids. To do this, White Leghorn pullets around 6 months of age should 
be fed either a 15% whole flaxseed or control diet and remain on their respective diets through 
their third year of lay. A subset of hens should be sacrificed and incidence of fibroids determined 
every six months. At the completion of the third year of lay, the remaining hens should be 
sacrificed, fibroid incidence determined, and fibroids collected for histological and molecular 
analysis. 
 There have not been many studies conducted analyzing the benefits of flaxseed 
supplementation as a treatment for uterine fibroids. After confirming our current results with 
further analyses on our samples in addition to conducting more animal trials, clinical trials 








A Dietary Intervention Study Assessing the Effects of Supplementation with 
10% Whole Flaxseed or Vitamin D3 on Oviductal Leiomyomas in the Hen  
 
Abstract: 
 Uterine leiomyomas, or fibroids, a leading cause of reproductive morbidity in 
reproductively-aged women, have a symptomatic incidence of around 40%. Symptoms include 
menorrhagia, pelvic pain, and infertility. These benign tumors are characterized by excessive 
production of extracellular matrix (ECM) components such as collagen. Leiomyomas are 
responsive to estrogen and progesterone, and occur more frequently as women age. Because the 
laying hen develops leiomyomas spontaneously as they age, they are a good animal model for 
studying the effects of diet on fibroids. White Leghorn hens, having completed their second year 
of lay, were randomly divided into three groups and fed either a control, 10% whole flaxseed-
supplemented, or vitamin D3-supplemented iso-caloric diet for 15 months. Blood was drawn 
from the same subset of hens every three months until the end of the trial. After 15 months on 
their respective diets, hens were euthanized. Oviducts were collected, and fibroids were counted, 
measured, and either flash frozen in liquid nitrogen or fixed in 10% neutral buffered formalin for 
further analysis. Leiomyoma incidence increased from 44% at the start of the trial to 78%, 74%, 
and 71% in the control, whole flaxseed, and vitamin D3 groups, respectively after 15 months. 
The number of leiomyomas per hen in all three groups increased significantly after fifteen 
months when compared to the baseline; there were no differences between groups after fifteen 
months. Plasma carbonylated protein levels decreased significantly in the whole flaxseed and 
vitamin D3-treated hens after 6 months on their respective diets and were significantly lower than 





downregulation of collagen I, TGF-β3, and PTGS2 gene expression in leiomyomas from hens 
fed the vitamin D3-supplemented diet after 15 months when compared to those from control 
hens. There were no differences between the whole flaxseed group and the control. Taken 
together, our data suggest an anti-inflammatory and anti-fibrotic effect of vitamin D3 on 
oviductal leiomyomas of the laying hen. We conclude that dietary intervention with vitamin D3 
should be further pursued as an effective non-invasive, long-term, fertility-preserving treatment 
for uterine fibroids in women. 
Introduction: 
 Uterine leiomyomas, or fibroids, have an incidence of approximately 77% and are the 
most common benign gynecological tumors in women of reproductive age4. Symptomatic 
fibroids cause pelvic pain, menorrhagia, and infertility5. Because of the significance of these 
symptoms and the lack of an effective, long-term treatment for fibroids, they are the leading 
cause of hysterectomies in the United States with an overall healthcare burden of approximately 
34.37 billion dollars annually2. Leiomyomas form from smooth muscle cells of the myometrium, 
are characterized by excessive ECM deposition, and estrogen and progesterone play a key role in 
their development3. Furthermore, environmental and genetic factors such as injury, stress, 
obesity, and race increase the risk of developing fibroids1,6. While scientists have uncovered 
some of the mechanisms regulating fibroids, a large part of their etiology still remains unknown. 
However, chronic inflammation has been hypothesized to play a role in their development7. 
Unfortunately, no long-term, non-invasive treatments for fibroids exist. Hysterectomy and 
myomectomy have been the gold-standard for fibroid treatment, with the latter allowing for 
fertility preservation. Because of this, there has been a growing interest in the potential use of 





in addition to vitamin D3 have shown some  potential as effective, long-term fibroid treatments 
due to their anti-inflammatory properites52–56,77–84. Previously, our laboratory validated the laying 
hen as an animal model for uterine fibroids91. The laying hen spontaneously develops 
leiomyomas on her oviduct as she ages. Furthermore, these tumors express higher levels of 
estrogen receptor (ER), progesterone receptor (PR), collagen I, and alpha smooth muscle actin 
(α-SMA) compared to normal oviduct tissue91. The purpose of our study was to determine the 
effects of dietary intervention with whole flaxseed and vitamin D3 on leiomyomas using the 
laying hen model. We hypothesized that supplementation with whole flaxseed or vitamin D3 
would have beneficial anti-inflammatory and anti-fibrotic effects on leiomyomas found in the 
oviduct of the laying hen. 
Materials and Methods: 
 Animals: 
 White Leghorn hens, aged 2 years and 9 months, were group-housed at the University of 
Illinois Poultry Research Facility. Hens were randomly assigned to treatment groups and were 
fed either a control (n=215), 10% whole flaxseed-supplemented (n=220), or vitamin D3-
supplemented (n=220) diet. The vitamin D3 supplement, Rovimix® Hy-D®, was kindly donated 
by DSM Nutritional Products, Inc (Parsippany, NJ, USA) and was included at a dose of 69 µg/kg 
based on previous data from DSM showing this level of supplementation to have biological 
effects on bone133. Table 3 shows the composition of each diet. Hens remained on their 
respective diets for a total of 15 months. At the beginning of the study, 25 hens were euthanized 
by CO2 asphyxiation to obtain a baseline incidence of leiomyomas; oviducts and leiomyomas 
were measured and collected. Blood samples were collected from the same subset of hens (50 





analyses. After 15 months, hens were euthanized by CO2 asphyxiation and oviducts and 
leiomyomas were measured and collected. All animal use was approved by the Institutional  
Animal Care and Use Committee at the University of Illinois at Urbana-Champaign. 
Leiomyoma Incidence and Size: 
 Leiomyoma incidence was calculated by taking the number of hens per treatment group 
that had at least one fibroid, dividing that by the total number of hens per treatment group, and 
multiplying by 100. Data are presented as a percentage. Leiomyoma size was determined by 
measuring fibroids in three dimensions using millimeters as the unit. Volume was calculated 
using the formula V=l x w x h x 0.523, which is the formula for the volume of an ellipsoid and 
has been used to calculate fibroid volume previously124. Data are presented as the mean fibroid 
volume per treatment group. 
Diet Composition 
Ingredient Control 10% Whole Flaxseed Vitamin D3 
Corn, % 67.64 59.04 67.59 
Flaxseed (whole), % 0.00 10.00 0.00 
Vitamin D3, (%)* 0.00 0.00 0.05 
SBM, % 18.30 18.30 18.30 
Corn Gluten Meal, % 3.00 0.60 3.00 
Solka Floc, % 0.00 1.00 0.00 
Limestone, % 8.75 8.75 8.75 
Dical, % 1.50 1.50 1.50 
Salt, % 0.36 0.36 0.36 
Vitamin Mix, % 0.20 0.20 0.20 
Mineral Mix, % 0.15 0.15 0.15 
DL-Met, % 0.10 0.10 0.10 
*Rovimix® included at a dose of 69 μg/kg/day 





25-hydroxyvitamin D3 via LC-MS/MS: 
 To confirm that the dose of vitamin D3 supplementation was significantly increasing 
vitamin D3 levels in in our hens throughout the trial, plasma samples were sent to Heartland 
Assays (Ames, IA, USA) for 25-hydroxyvitamin D3 analysis via LC-MS/MS. 10 samples from 
each of the following time points and treatment groups were assayed: baseline (prior to start of 
trial), vitamin D3 3 months, vitamin D3 6 months, vitamin D3 9 months, vitamin D3 15 months, 
and control 15 months. We followed the same hens throughout as many time points as possible. 
DSM generously covered the costs of this analysis. 
Carbonylated Protein Assay: 
 To obtain a measure systemic levels of oxidative stress in our hens, we measured levels 
of oxidized proteins in the plasma using the Protein Carbonyl Colorimetric Assay Kit (Cayman 
Chemicals, Ann Arbor, MI, USA) per manufacturer’s instructions. This kit uses the reaction 
between 2,4-dinitrophenylhydrazine and protein carbonyls to form a Schiff base thus producing a 
hydrazone134. The protein-hydrazone complex can be measured spectrophotometrically134. 
Samples were plated in duplicate with n=12 per treatment per time point. A pooled plasma 
sample was used to determine inter-assay variation across plates. 
ELISA’s: 
 Enzyme-linked immunosorbent assays were performed to measure systemic levels of the 
inflammatory cytokines TNF-α and interferon gamma (IFN-γ). The TNF-α kit was purchased 
from LifeSpan Biosciences, Inc. (LS-F23677, Seattle, WA, USA) and the IFN-γ kit was 





ELISAs were performed according to the manufacturer’s instructions. Samples were plated in 
duplicate with n=7 per treatment per timepoint. 
RNA Isolation and cDNA synthesis: 
 RNA was isolated from fibroids using the Trizol method. Briefly, 50-100 mg of tissue 
was homogenized in 1 mL of Trizol using 2mm Tungsten Carbide beads and the TissueLyserII, 
both from Qiagen. Fibroids were macerated for 25 second intervals with 5 seconds on ice 
between intervals. On average, it took 2-3 intervals for samples to be completely homogenized. 
Following homogenization, 200 µL of chloroform were added to sample tubes. Tubes were 
vortexed and incubated at room temperature for 10 minutes. Following incubation, tubes were 
centrifuged at 12,000xg for 15 minutes at 4⁰C in a microcentrifuge. After centrifugation, the 
aqueous layer was extracted. 500 µL of isopropanol and 5 µL of glycogen (for pellet 
visualization) were added to the aqueous layer and samples were vortexed and incubated 
overnight at -20⁰C. The following day, samples were centrifuged at 12,000xg for 15 minutes at 
4⁰C in a microcentrifuge and the supernatants were discarded. Pellets were washed with 75% 
ethanol and centrifuged at 12,000xg for 5 minutes at 4⁰C. Supernatants were again discarded and 
pellets were allowed to air dry. Finally, pellets were re-suspended in 22 µL of nuclease free 
water. RNA concentration, A260/280, and A260/230 were measured using the Nanodrop. cDNA 
was synthesized from RNA samples using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA, USA) per the manufacturer’s instructions. 
qRT-PCR: 
Quantitative reverse transcription PCR was performed using a TaqMan ABI 7900 real 





Urbana-Champaign. Changes in mRNA levels of collagen I (Gg03325897_m1), PTGS2 
(Gg03320004_m1), and TGF-β3 (Gg03371523_m1) in leiomyomas of hens from each of the 
treatment groups (after 15 months on the diets) were determined. 18S (Hs99999901_s1) was 
used as the housekeeping gene. All primer probe sets were purchased from Applied Biosystems 
(TaqMan™, Foster City, CA, USA). Data are presented as relative fold change between the 
control and flaxseed and control and vitamin D3 treatments. 
It is important to note that due to high variation in our housekeeping gene between 
samples, our relative fold change average of our control samples was not equal to 1. Therefore, 
we divided our control and flaxseed fold change averages by the average fold change value of 
the controls to accurately depict relative fold change in our graphs. Statistical analyses were not 
performed on these values as they induced artificial significance. 
Statistical Analyses: 
All statistical analyses were computed using GraphPad Prism 7.0. The D’Agonstino and 
Pearson normality test and the one-way ANOVA followed by multiple comparison’s test were 
used. For data that did not follow Gaussian distribution, the Kruskal-Wallis non-parametric test 







Measurement of 25-hydroxyvitamin D3 via LC-MS/MS: 
 A subset of plasma samples from baseline, 3- 6- 9- 15- month vitamin D, and 15-month 
control hens were evaluated by LC-MS/MS for levels of 25-hydroxyvitamin D3.  The 25-
hydroxyvitamin D3 levels were significantly increased at all timepoints in the vitamin D3 group 
when compared to both the baseline and 15-month control hens, confirming that the 69 
µg/kg/day dose of Rovimix was leading to increased blood levels  in our laying hens throughout 
the entire trial (Figure 14). There was no significant difference in 25-hydroxyvitamin D3 levels 
between baseline control hens at the start of the trial and in control hens after 15 months (Figure 
14). 
  
Figure 14: 25-Hydroxyvitamin D3 via LC-MS/MS. Vitamin D supplemented at a dose of 69 µg/kg/day 
was biologically active in our laying hens throughout the course of the study. Black bars compare 
vitamin D time points versus the hens prior to the trial. Grey bars compare vitamin D time points versus 






Leiomyoma Incidence, Number of Leiomyomas per Hen, and Size: 
 Incidence of leiomyomas increased from 44% at the start of the trial to 78%, 74%, and 
71% in the control, whole flaxseed, and vitamin D3 groups, respectively, after 15 months on 
each diet (Figure 15A). While the average number of leiomyomas per hen increased 
significantly between the start of the trial and the end, the average number of fibroids per hen 
was slightly decreased in both the whole flaxseed (3.02 per hen) and vitamin D3 (2.72 per hen) 
groups when compared to the controls (3.84 per hen) after 15 months, although this change was 
not significant (Figure 15B). There were no differences in the average size of leiomyomas 
between hens fed the control, whole flaxseed, or vitamin D3 diets after 15 months (Figure 15C). 
  
Figure 15: A) % Incidence of leiomyomas from hens before the trial compared with those from hens fed 
the control, whole flaxseed, and vitamin D diets. Incidence increased from ~40% to ~80% between the 
second and third year of lay in each of the treatment groups. B) Number of fibroids per hen was 
significantly increased between the baseline and all treatment groups after 15 months. There was no 
significant difference in number of fibroids per hen between the treatment groups. C) There were no 






Carbonylated Protein Levels in Plasma: 
 Carbonylated protein levels in plasma were measured to assess systemic levels of 
oxidative stress. We found that carbonylated protein levels in plasma were significantly reduced 
in hens fed the 10% whole flaxseed diet as well as in hens fed the vitamin D3 diet after 6 months 
on the diet, and these levels continued to remain significantly lower throughout the remaining 
time points of the trial (Figure 16B-C). There were no changes in plasma levels of carbonylated 
proteins in the control hens throughout the course of the study (Figure 16A). In addition, 
carbonylated protein levels in plasma were significantly reduced in both the whole flaxseed and 
vitamin D3 groups when compared to the control group after 9 months (Figure 17D). These 
levels remained significantly lower than those of the control hens throughout the remainder of 
the trial (Figure 17E-F). 
Figure 16: A Comparison of Protein Carbonyl Content by Treatment Group. A) Carbonylated protein 
content in control hens at 0 (n=11), 3 (n=10), 6 (n=9), 9 (n=12), 12 (n=11), and 15 (n=12) months. There 
were no differences in control hens at any time point when compared to month 0. B) Carbonylated protein 
content in hens fed the 10% whole flaxseed diet at 0 (n=12), 3 (n=12), 6 (n=11, p=0.0083), 9 (n=11, 
p=0.0001), 12 (n=11, p=0.0001), and 15 (n=12, p=0.0001) months. Hens had significantly reduced protein 
carbonyl content in the plasma after 6 months on the whole flaxseed diet when compared to month 0. These 
levels remained significantly lower at months 9, 12, and 15. C) Carbonylated protein content in hens fed the 
vitamin D diet at 0 (n=11), 3 (n=12), 6 (n=9, p=0.0439), 9 (n=11, p=0.0007), 12 (n=10, p=0.0001), and 15 
(n=11, p=0.0001) months. Hens had significantly reduced protein carbonyl content in the plasma after 6 
months on the vitamin D diet when compared to month 0. These levels remained significantly lower at 






 In addition to assessing oxidative stress, we also wanted to determine whether there were 
changes in systemic levels of the inflammatory cytokines TNF-α and IFN-γ, and thus, performed 
ELISA assays for each. Unfortunately, due to the high variation between samples (all CV’s were 
≥30%) of the same treatment group, at the same time points, and within duplicates, we were not 
able to draw any conclusions about levels of TNF-α in the plasma. Furthermore, several samples 
from all three treatment groups were too low to detect. This occurred at all time points measured 
(0, 3, 6, 9, 12, and 15 months). We were not able to detect TNF-α in any of our 15-month 
samples. The upper detection limit of this assay is 2000 pg/mL and the lower detection limit is 
Figure 17: A Comparison of Protein Carbonyl Content between Treatment Groups. A–C) There were no 
significant differences in plasma levels of carbonylated proteins between treatment groups at months 0, 3, or 6. 
Control n=11,10,9 (month 0,3,6), Whole Flaxseed n=12,12,11 (month 0,3,6), and Vitamin D n=11,12,9 (month 
0,3,6). D–F) Protein Carbonyl Content in the plasma of hens fed the 10% whole flaxseed (n=11,11,12; month 
9,12,15) or vitamin D (n=11,11,12; month 9,12,15) diets were significantly reduced at month 9, 12, and 15 






31.25 pg/mL. It does not appear that there were any differences in plasma levels of TNF-α 
between treatment groups at any time during the study (Figure 18). Figure 18 does depict a 
significant increase in plasma TNF-α levels after three months in the vitamin D group, however, 
because the coefficient of variation was ~50%, we do not believe these values are representative 
of actual levels of TNF-α in these hens. This experiment should be repeated to determine the true 
levels of TNF-α in the plasma of hens from each treatment group at all time points. IFN-γ was 
not detectable in the plasma of our hens in any treatment group or time point (data not shown). 
  
Figure 18: Plasma levels of TNF-α from hens fed either the control, 10% whole flaxseed, or vitamin D diet 
after A) 0 months, B) 3 months, C) 6 months, D) 9 months, and E) 12 months. Number of plasma samples 
ran for analysis: N=7/trt/timepoint. Number of plasma samples with levels of TNF-α on the linear portion 
of the standard curve: Month 0: control n=7, whole flax n=5, vit D n=2. Month 3: control n=7, whole flax 
n=6, vit D n=6. Month 6: control n=7, whole flax n=6, vit D n=5. Month 9: control n=4, whole flax n=6, vit 
D n=4. Month 12: control n=6, whole flax n=1, vit D n=3. Upper limit of detection: 2000 pg/mL. Lower 





qRT-PCR Analysis of Gene Expression: 
 mRNA expression levels of collagen I, TGF-β3, and PTGS2 were compared in 
leiomyomas from hens fed either the control, 10% whole flaxseed, or vitamin D3 diets. Fibroids 
from hens fed the vitamin D3 diet showed significant downregulation of all three genes when 
compared to those from control hens, whereas there were no changes in collagen I (p=0.88) 
expression in addition to non-significant decreases in expression of TGFβ-3 (p=0.48) and PTGS2 
(p=0.49) in fibroids from hens fed the whole flaxseed diet when compared to the controls 
(Figure 19). 
Discussion: 
 Uterine leiomyomas are the most common benign gynecological tumors found in women 
of reproductive age and cause a significant burden on women’s healthcare due to the high cost of 
treatment. Hysterectomy, myomectomy, and uterine artery embolization have become routine 
treatments for fibroids, and currently no effective long-term, non-surgical options for 
Figure 19: Collagen I, TGF-β3, and PTGS2 mRNA Expression via qRT-PCR. A) Collagen I was significantly 
downregulated in fibroids from hens fed the vitamin D diet (n=12) when compared to those from hens on the 
control diet (n=8) (p=0.02). B) Leiomyomas from the vitamin D group (n=12) expressed lower levels of TGF-β3 
than those from the control group (n=8) (p=0.003). C) PTGS2 was significantly downregulated in vitamin D 
fibroids (n=12) than in fibroids from hens fed the control diet (n=8) (p=0.001). There were no significant 
differences in collagen I, TGF-β3, or PTGS2 expression between fibroids from hens on the flaxseed diet 





leiomyomas exist. Thus, the purpose of our study was to assess the efficacy of dietary 
intervention with whole flaxseed and vitamin D as a therapy for fibroids found in the oviduct of 
the laying hen. Overall, our data show that dietary supplementation with whole flaxseed is 
beneficial to the general health of the laying hen while vitamin D supplementation has a 
therapeutic effect on oviductal leiomyomas. Hens fed a diet supplemented with whole flaxseed 
or vitamin D3 had significantly lower plasma levels of carbonylated proteins compared to hens 
fed the control diet. Hens fed the vitamin D3 diet had significantly decreased levels of collagen I, 
TGF-β3, and PTGS2 mRNA expression. 
Consistent with our laboratory’s previous finding of an increase in leiomyoma incidence 
(from 45% to 73.19%) in White Leghorn hens between their second and third years of lay, we 
also found that leiomyoma incidence increased in White Leghorn hens from 44% at the start of 
our trial (end of the second year of lay) to 78%, 74%, and 71% in the control, 10% whole 
flaxseed, and vitamin D3 treatments after 15 months, respectively91. Another study reported a  
100% incidence of leiomyomas in 5-year-old White Leghorn hens90. While this incidence is 
approximately 25% higher than our reported findings, the hens in this study were two years older 
than ours. We suspect that we would have reported similar increased incidences had our study 
continued past 15 months. 
 We did not find any significant differences in number of fibroids per hen or leiomyoma 
volume between the three treatment groups. This is consistent with our reported findings in 
Chapter 2 of this thesis for hens fed a similar, 15% flaxseed diet for 12 months. However, a 
previous trial assessing the effects of 10% whole flaxseed on oviductal leiomyomas in the laying 
hen found a significant decrease in the size of leiomyomas from hens fed the flaxseed diet versus 





require a longer period of treatment (18-24 months). In contrast to our results, Halder et al. found 
that 1,25-dihydroxyvitamin D3 reduced the size of leiomyomas in the Eker rat model after 3 
weeks83. This difference could be due to a variety of factors. First of all, species differences 
could account for the discrepancy in results since the rat is a mammal and the chicken an avian 
species. Secondly, and the more likely reason, is that the tumors found in the Eker rat are more 
similar to leiomyosarcomas, which are malignant tumors, rather than the benign leiomyomas 
found in our laying hen model and may be more responsive to changes in Vitamin D87. 
 To measure oxidative stress, we assessed changes in levels of carbonylated proteins in the 
plasma of a subgroup of our hens. Carbonylated protein levels in the blood is a recognized  
marker of oxidative stress134–136. Plasma was collected every three months from the start of the 
trial from the same birds. We found that the hens fed the whole flaxseed and vitamin D3 diets 
had a significantly lower carbonylated protein level in their plasma nine months after beginning 
their respective diets compared to hens fed the control diet. These levels remained significantly 
lower throughout the rest of the trial. Oxidative stress is associated with inflammation137–139. The 
lower levels of carbonylated proteins found in our flaxseed and vitamin D3 treated hens suggests 
that these hens were experiencing less oxidative stress and inflammation compared to hens fed 
the control diet. Unfortunately, we were not able to obtain any accurate measures of 
inflammatory cytokines to confirm these results. In the future, we would like to measure the pro-
inflammatory cytokines IL-1β and IL-6 along with the anti-inflammatory cytokine IL-10. 
 We also investigated potential mechanisms by which flaxseed and vitamin D3 exert their 
effects on leiomyomas in the laying hen, by performing qRT-PCR to assess effects on mRNA 
expression levels of collagen I, TGF-β3, and PTGS2. It is important to note that our 





There are a few possible reasons for this. First, it is possible that 18S isn’t the best housekeeping 
gene for our samples and species. However, previous work with leiomyomas in the laying hen 
from our lab used 18S as a housekeeping gene successfully, so this is unlikely the case93. 
Second, our extracted RNA was analyzed on a Nanodrop Spectrophotometer prior to cDNA 
synthesis and were not treated with DNase. Because the Nanodrop cannot differentiate between 
RNA and DNA, it is possible that the amplification we witnessed was DNA amplification and 
not mRNA amplification. Our 18S primer-probe was designed within a single exon whereas our 
collagen I, TGFβ-3, and PTGS2 primer-probes were designed across an exon junction, thus 
making DNA contamination and amplification in our housekeeping samples probable. 
Leiomyomas from hens fed a diet supplemented with vitamin D3 for 15 months exhibited 
significantly decreased expression levels of all three genes when compared to leiomyomas from 
hens fed the control diet. PTGS2 is the gene that encodes COX-2, the inducible enzyme in the 
prostaglandin pathway. The COX-2/prostaglandin pathway has been strongly implicated in a 
variety of inflammatory diseases, including cancer, and downregulating COX-2 expression or 
action has been shown to be potentially beneficial to inhibiting disease progression61–63,95,103. 
Leiomyomas from hens fed the whole flaxseed treatment showed a modest, non-significant 
decrease in PTGS2 mRNA expression compared to the control group; which is inconsistent with 
our data presented in the previous chapter. Due to limited resources, we were not able to run 
qRT-PCR on an identical number of fibroids from the control and whole flaxseed groups 
(n=8/group) compared to the vitamin D group (n=12). It is possible that increasing our n would 
lower the variation in our control treatment group, improving our statistical rigor. 
Previously, Machado et al. reported that leiomyomas from the laying hen expressed 





component of ECM and TGF-β is a pro-fibrotic cytokine with higher levels of expression in 
leiomyomas than in normal myometrium and has been shown to induce fibronectin expression in 
leiomyoma smooth muscle cells120. TGF-β3 has also been shown to stimulate the production of 
collagen I122. The decreased expression of collagen I and TGF-β3 in hens fed the diet 
supplemented with vitamin D3 suggests that vitamin D3 may exert its effects directly on TGF-β3 
which then leads to a decrease in collagen I production quite possibly through the Smad 
signaling pathway. The Smad signaling pathway consists of eight intracellular proteins, known 
as Smads (Smad1 through Smad8) that transport signals from the cell membrane to the 
nucleus121. TGF-β is an activator of the Smad pathway and regulates the transcription of genes 
responsible for cellular proliferation and ECM deposition121. Several papers have shown vitamin 
D3’s negative regulation of TGF-β and Smad signaling in fibrosis-related diseases, many of 
which are reviewed by Shany et al140. Induction of vitamin D receptor (VDR) has been shown to 
be important in vitamin D3’s regulation of TGF-β/Smad in cutaneous injury, systemic sclerosis, 
and intestinal fibrosis69–71. Halder et al. clearly demonstrated the ability of vitamin D3 to 
downregulate pro-fibrotic genes induced by TGF-β through Smad signaling in cultured human 
leiomyoma cells84. We have not yet investigated specific signaling pathways in regard to vitamin 
D3’s effects on fibroids. Other pathways, such as MAPK/ERK and wingless-type (Wnt)/β-
catenin (or several pathways acting simultaneously through an additive effect), could explain the 
mechanism behind vitamin D3’s potential therapeutic effects on leiomyomas. Further research is 
needed to elucidate the mechanisms involved. However, our in vivo data suggest that 






Conclusions and Future Directions: 
  Our data show that dietary supplementation with whole flaxseed and vitamin D3 
decreases systemic oxidative stress, an indicator of inflammation and general health status, in the 
laying hen model of uterine fibroids. We also provide evidence that vitamin D3 has beneficial, 
therapeutic effects on leiomyomas found in the oviduct of the laying hen and that TGF-β3 is a 
possible target of vitamin D3. Based on these findings, we recommend the pursuit of dietary 
intervention with vitamin D3 as a treatment for women with uterine fibroids because it is 
inexpensive and easily accessible. 
While our evidence is supportive for an anti-inflammatory effect of vitamin D3 and of 
flaxseed, there is more work that should be done to confirm our findings. As mentioned in our 
discussion, our 18S housekeeping gene did not run properly during our qRT-PCR experiment. 
To validate the results we obtained, a few steps should be taken prior to repeating the 
experiment. First, isolated RNA should be treated with DNase to digest any DNA in the sample. 
Secondly, more thorough quality control of our RNA should be conducted prior to running qRT-
PCR, such as analysis using an Agilent Bioanalyzer machine. Third, a housekeeping gene 
designed across an exon junction would minimize the risk of DNA contamination in our samples 
interfering with the true results of the qRT-PCR experiment. Our 18S primer-probe was a 
Taqman assay from Applied Biosystems and was designed to target human 18S. Because of 
previous results from our lab with this specific primer in chicken samples, we chose to use this 
assay again. However, there is a GAPDH Taqman assay available that is designed for the 
chicken as a target species in addition to spanning an exon junction. 
We also looked at oxidative stress as a marker of inflammation in our plasma samples, 





these same blood samples. In further reading of the literature, it seems that measuring plasma 
levels of IL-1β, IL-6, and IL-10 would provide a more comprehensive picture of the 
inflammatory state of these hens. Therefore, we would like to perform additional ELISAs to 
measure these cytokines. In addition, we quantitated collagen I, TGF-β3, and PTGS2 gene 
expression using qRT-PCR, but we did not look at protein expression of these markers. 
Performing a western blot for the proteins translated from these genes (or a hydroxyproline assay 
to assess collagen) would be a good way to determine if the changes we saw at the mRNA level 
are translated to functional protein, thus strengthening our evidence. In our discussion, we 
mentioned vitamin D3 exerting its effects through the TGF-β/Smad signaling pathway. To test 
this hypothesis, performing western blots to assess changes in functional protein levels of 
pSmad2, pSmad3, total Smad2, and total Smad3 would give us more detailed information on the 
regulation of this pathway by vitamin D3. It would also be beneficial to use this method to look 
at potential changes in VDR levels. 
In our study we had a limited number of hens available to us. Therefore, we had to limit 
our treatment groups to control, whole flaxseed, and vitamin D3 and were unable to include a 
combined treatment group of 10% whole flaxseed plus vitamin D3. We are very interested in 
determining whether the combined dietary supplements would have an additive protective effect 
on leiomyomas in the laying hen. Furthermore, we had to limit our current study to only 15 
months of treatment. Our findings in Chapter 2 suggest that the length of time on these diets is 
the key to their success. Thus, we would like to examine the effects of these diets after 24 
months or more. Additionally, our diets were initiated at the completion of the second year of 
lay. It is possible that these agents might work better as preventatives for the development of 





development of leiomyomas by starting hens on these diets when they reach sexual maturity (~6 
months of age) and keeping them on these diets until after their third year of lay. 
Clinical trials are an important part of medical research to confirm that therapies found to 
be safe and effective in animal models are safe and effective in humans and work better than a 
placebo. Therefore, we are interested to see the implications of dietary supplementation with 
whole flaxseed or vitamin D3 on women with uterine fibroids. We hypothesize that long-term 
treatment with these supplements will shrink fibroids and reduce symptoms such as pelvic pain 
or discomfort and menorrhagia. Furthermore, vitamin supplementation is something that can 
begin at any stage in life which poses the question: would supplementation with vitamin D3 
during the peripubertal or teenage years (and continuation throughout adulthood) prevent uterine 
leiomyoma development in women? Moving forward with clinical studies to answer these 
questions will help to provide long-term, non-surgical treatment strategies to women suffering 
from symptomatic uterine leiomyomas and their clinicians. 
 In summary, we saw an improvement in overall health indicators of our laying hens after 
15 months of either whole flaxseed or vitamin D3 supplementation, and vitamin D3 significantly 
reduced the expression of genes important to the development of leiomyomas. However, we did 
not see any changes in the size and incidence of oviductal leiomyomas in our laying hens after 
15 months on their diets. Additional experiments should be completed to confirm our findings 
and add to the growing body of evidence supporting dietary intervention as a relatively cheap, 
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Gomori’s Trichrome Stain: 
Reagent Preparation: 
 Meyer’s Hematoxylin: filter before use 
 Bouin’s Solution: VERY VOLATILE, USE IN FUME HOOD!!!!! 
 0.2% Acetic Acid (250 mL): 
o Add 0.5 mL Glacial Acetic Acid to 250 mL MilliQ water 
o ALWAYS DO WHAT YOU OUGHTA, ADD ACID TO WATER 
 Gomori’s Trichrome Stain (store in refrigerator, good for approx. 2 months): 
o Chrometrope 2R – 0.6 g 
o Fast Green FCF – 0.3 g 
o 10% Phosphotungstic Acid – 10.0 mL 
o Deionized Water – 89.0 mL 
o Glacial Acetic Acid – 1.0 mL 
o Adjust pH to 3.4 using 1 M NaOH 
Procedure: 
 Put water bath into fume hood and turn on to 60ᵒC 
 Fill staining tub with Bouin’s solution, place into water bath, and heat to 60ᵒC 
o DO NOT OPEN BOUIN’S OUTSIDE OF FUME HOOD!!!! 
 Deparaffinization & Rehydration: 
o Xylenes I – 5 min 
o Xylenes II – 5 min 
o Xylenes III – 5 min 
o 100% EtOH I – 1 min 
o 100% EtOH II – 1 min 
o 70% EtOH – 1 min 
o Tap water – 1 min 
 Incubate slides for 1 hour in Bouin’s solution at 60ᵒC 
o Check periodically- Bouin’s solution is very volatile due to its picric acid 
content!!! 
o After incubation is complete, allow Bouin’s to cool down in fume hood before 
cleanup during later step 
 Wash slides in running deionized water until liquid is clear 
 Place slides into MilliQ water – 2 min 
 Place slides into Meyer’s Hematoxylin – 5 min 





o Bouin’s solution is good for ~2 days, so you can reuse this solution if you will be 
doing multiple runs, otherwise, dispose of into liquid waste container labeled 
“Bouin’s” 
o Use a large beaker of deionized water to rinse Bouin’s container in the fume 
hood. Dump from Bouin’s container into liquid waste container labeled “Bouin’s” 
until water comes out clear. 
o Place any contaminated paper towels, gloves, etc. into a solid waste container 
labeled “Bouin’s” 
 Wash slides in running tap water until liquid is clear 
 Incubate in Gomori’s Trichrome Stain – 10 min 
 Dip 3 times in 0.2% Acetic Acid 
 Dehydration and Clearing: 
o 70% EtOH – 1 min 
o 80% EtOH – 1 min 
o 90% EtOH – 1 min 
o 100% EtOH II – 1 min 
o 100% EtOH I – 1 min 
o Xylenes I – 1 min 
o Xylenes II – 1 min 
o Xylenes III – 1 min 






Immunohistochemsitry—Proliferating Cell Nuclear Antigen: 
PCNA Antibody (PC10), Novus Biologicals, NB500-106 
ABC Method, Mouse IgG kit 
Perform all steps at room temperature unless otherwise noted 
Incubation must be performed in moist chamber 
Do not allow sections to dry out 
Day 1: 
 Deparaffinization & rehydration: 
o Xylenes I – 5 min 
o Xylenes II – 5 min 
o Xylenes III – 5 min 
o 100% EtOH I – 1 min 
o 100% EtOH II – 1 min 
o 70% EtOH – 1 min 
o Tap water – 1 min 
 Antigen retrieval: 
o Boil in 1:10 DAKO – 20 min 
 Cool down to room temperature 
 Rinse in PBST – 5 min 
 Inactivation of endogenous peroxidase: 
o Place in 0.3% H2O2/MeOH in dark – 15 min 
 Rinse in PBST – 3 x 5 min 
o Encircle each section with a PAP pen while rinsing in PBST 
 Blocking of non-specific binding: 
o Incubate in 5% normal horse serum (diluted in PBST) from mouse kit – 60 min 
 Incubate in 1:1000 PCNA antibody (diluted in 1% BSA/PBST) – Overnight @ 4ᵒC 
 
Day 2: 
 Rinse in PBST – 3 x 5 min 
 Incubate in secondary antibody: 
o 1:100 Biotinylated Anti-Mouse (diluted in 1% BSA/PBST) – 60 min 
 Prepare ABC solution 30 min before use: 
o 50:1:1 – 2.5 mL 1% BSA/PBST: 1 drop A: 1 drop B 
 Rinse in PBST – 3 x 5 min 
 Incubate in ABC solution – 30 min 





 DAB reaction (see kit for preparation) – 30 seconds per slide 
o Stop DAB reaction in tap water 
 Counterstain in Meyer’s Hematoxylin – 1 min 
 Wash in tap water until water runs clear 
 Dehydration & clearing: 
o 70% EtOH – 1 min 
o 80% EtOH – 1 min 
o 90% EtOH – 1 min 
o 100% EtOH II – 1 min 
o 100% EtOH I – 1 min 
o Xylenes I – 1 min 
o Xylenes II – 1 min 
o Xylenes III – 1 min 







Immunohistochemistry—Von Willebrand Factor: 
VWF Antibody, Agilent Pathology Solutions, A008229-5 
ABC Method, Rabbit IgG kit 
Perform all steps at room temperature unless otherwise noted 
Incubation must be performed in moist chamber 
Do not allow sections to dry out 
Day 1: 
 Deparaffinization & rehydration: 
o Xylenes I – 5 min 
o Xylenes II – 5 min 
o Xylenes III – 5 min 
o 100% EtOH I – 1 min 
o 100% EtOH II – 1 min 
o 70% EtOH – 1 min 
o Tap water – 1 min 
 Antigen retrieval: 
o Boil in 1:10 DAKO – 20 min 
 Cool down to room temperature 
 Rinse in PBST – 5 min 
 Inactivation of endogenous peroxidase: 
o Place in 0.3% H2O2/MeOH in dark – 15 min 
 Rinse in PBST – 3 x 5 min 
o Encircle each section with a PAP pen while rinsing in PBST 
 Blocking of non-specific binding: 
o Incubate in 5% normal goat serum (diluted in PBST) from rabbit kit – 60 min 
 Incubate in 1:400 VWF antibody (diluted in 1% BSA/PBST) – Overnight @ 4ᵒC 
 
Day 2: 
 Rinse in PBST – 3 x 5 min 
 Incubate in secondary antibody: 
o 1:100 Biotinylated Anti-Rabbit (diluted in 1% BSA/PBST) – 60 min 
 Prepare ABC solution 30 min before use: 
o 50:1:1 – 2.5 mL 1% BSA/PBST: 1 drop A: 1 drop B 
 Rinse in PBST – 3 x 5 min 
 Incubate in ABC solution – 30 min 





 DAB reaction (see kit for preparation) – 30 seconds per slide 
o Stop DAB reaction in tap water 
 Counterstain in Meyer’s Hematoxylin – 1 min 
 Wash in tap water until water runs clear 
 Dehydration & clearing: 
o 70% EtOH – 1 min 
o 80% EtOH – 1 min 
o 90% EtOH – 1 min 
o 100% EtOH II – 1 min 
o 100% EtOH I – 1 min 
o Xylenes I – 1 min 
o Xylenes II – 1 min 
o Xylenes III – 1 min 







NF-κB p65 Antibody, Abcam, AB16502 
ABC Method, Rabbit IgG kit 
Perform all steps at room temperature unless otherwise noted 
Incubation must be performed in moist chamber 
Do not allow sections to dry out 
Day 1: 
 Deparaffinization & rehydration: 
o Xylenes I – 5 min 
o Xylenes II – 5 min 
o Xylenes III – 5 min 
o 100% EtOH I – 1 min 
o 100% EtOH II – 1 min 
o 70% EtOH – 1 min 
o Tap water – 1 min 
 Antigen retrieval: 
o Boil in 1:10 DAKO – 20 min 
 Cool down to room temperature 
 Rinse in PBST – 5 min 
 Inactivation of endogenous peroxidase: 
o Place in 0.3% H2O2/MeOH in dark – 15 min 
 Rinse in PBST – 3 x 5 min 
o Encircle each section with a PAP pen while rinsing in PBST 
 Blocking of non-specific binding: 
o Incubate in 5% normal goat serum (diluted in PBST) from rabbit kit – 60 min 
 Incubate in 1:1000 NF-κB p65 antibody (diluted in 1% BSA/PBST) – Overnight @ 4ᵒC 
 
Day 2: 
 Rinse in PBST – 3 x 5 min 
 Incubate in secondary antibody: 
o 1:100 Biotinylated Anti-Rabbit (diluted in 1% BSA/PBST) – 60 min 
 Prepare ABC solution 30 min before use: 
o 50:1:1 – 2.5 mL 1% BSA/PBST: 1 drop A: 1 drop B 
 Rinse in PBST – 3 x 5 min 
 Incubate in ABC solution – 30 min 





 DAB reaction (see kit for preparation) – 30 seconds per slide 
o Stop DAB reaction in tap water 
 Counterstain in Meyer’s Hematoxylin – 1 min 
 Wash in tap water until water runs clear 
 Dehydration & clearing: 
o 70% EtOH – 1 min 
o 80% EtOH – 1 min 
o 90% EtOH – 1 min 
o 100% EtOH II – 1 min 
o 100% EtOH I – 1 min 
o Xylenes I – 1 min 
o Xylenes II – 1 min 
o Xylenes III – 1 min 







Nitrotyrosine Antibody, Millipore Sigma, 06-284 
ABC Method, Rabbit IgG kit 
Perform all steps at room temperature unless otherwise noted 
Incubation must be performed in moist chamber 
Do not allow sections to dry out 
Day 1: 
 Deparaffinization & rehydration: 
o Xylenes I – 5 min 
o Xylenes II – 5 min 
o Xylenes III – 5 min 
o 100% EtOH I – 1 min 
o 100% EtOH II – 1 min 
o 70% EtOH – 1 min 
o Tap water – 1 min 
 Antigen retrieval: 
o Boil in 1:10 DAKO – 20 min 
 Cool down to room temperature 
 Rinse in PBST – 5 min 
 Inactivation of endogenous peroxidase: 
o Place in 0.3% H2O2/MeOH in dark – 30 min 
 Rinse in PBST – 3 x 5 min 
o Encircle each section with a PAP pen while rinsing in PBST 
 Blocking of non-specific binding: 
o Incubate in 5% normal goat serum (diluted in PBST) from rabbit kit – 60 min 
 Incubate in 1:400 Nitrotyrosine antibody (diluted in 1% BSA/PBST) – Overnight @ 4ᵒC 
 
Day 2: 
 Rinse in PBST – 3 x 5 min 
 Incubate in secondary antibody: 
o 1:100 Biotinylated Anti-Rabbit (diluted in 1% BSA/PBST) – 60 min 
 Prepare ABC solution 30 min before use: 
o 50:1:1 – 2.5 mL 1% BSA/PBST: 1 drop A: 1 drop B 
 Rinse in PBST – 3 x 5 min 
 Incubate in ABC solution – 30 min 





 Incubate in AEC Solution – 5 min in dark 
o Rinse in 3 changes of DI water 
 Counterstain in Meyer’s Hematoxylin – 2 min 
 Wash in DI water until water runs clear 






Sudan Black B Stain: 
Reagent Preparation: 
 Sudan Black B Stain: 
o Sudan Black B – 2.1 g 
o 70% EtOH – 300 mL 
o Mix reagents in low-light conditions. 
o Filter twice with Whatman Filter Paper. 
o Store at room temperature in dark. 
Procedure: 
 Deparaffinization & Rehydration: 
o Xylenes I – 5 min 
o Xylenes II – 5 min 
o Xylenes III – 5 min 
o 100% EtOH I – 1 min 
o 100% EtOH II – 1 min 
o 70% EtOH – 1 min 
 Place slides in Sudan Black B solution at room temperature overnight 
 Dehydration and Clearing: 
o 70% EtOH – until sections are pale grey 
o 100% EtOH II – 1 min 
o 100% EtOH I – 1 min 
o Xylenes I – 1 min 
o Xylenes II – 1 min 
o Xylenes III – 1 min 
Mount slides with Clearmount 
Toluidine Blue Stain (courtesy of Karen Doty): 
Procedure: 
 Deparaffinize sections and hydrate through graded alcohols to water. 
 Stain slides in 0.1% aqueous toluidine blue solution for 10 min. 
 Rinse in distilled water. 
 Dehydrate quickly through 95% and 100% alcohol. This step differentiates the stain and 
must be checked carefully. 







RNA Isolation and cDNA Synthesis: 
Homogenization 
 Add 50-100 mg fibroid tissue to a 2.0-ml Safe-Lock Eppendorf tube containing 1 ml of 
Trizol Reagent and enough 2mm Tungsten Carbide beads (Qiagen) to fill the conical 
portion of the tube. 
 
 Macerate fibroid tissue using TissueLyserII from Qiagen for 25 second intervals. Place 
on wet ice for 5 seconds between intervals. 
 
o Typically takes 2-3 intervals of homogenization. 
 
 Remove supernatant and add to fresh tubes containing 0.2ml chloroform per ml Tri 
Reagent; mix vigorously by shaking/vortexing for 15 sec.  
 
 Incubate tubes at RT for at least 10 min. 
 
 Centrifuge mixture at 12,000xg for 15 min at 4oC. 
 
RNA isolation 
 Transfer upper aqueous (clear) phase to fresh tubes containing 0.5 ml of isopropanol (2-
propanol) per ml of Tri Reagent. NOTE: be sure to leave “buffy coat” undisturbed to 
minimize incidence of a contaminant “bubble” during RNA isolation. Vortex well. Save 
interphase and phenol/chloroform layer for DNA extraction and store in either -20 
oC (processing within the month) or -80 oC (processing past a month). 
 
o Note: To see pellet when using a small amount of cells/tissue, dilute glycogen 
1:10 and add 5ul to isopropanol before transferring upper aqueous phase. 
 
 Allow sample to stand for at least 10 min at –80oC, then at least 10 min at –20oC. 
Alternatively, hold sample at –20oC for at least 20 min or overnight at 4oC or –20oC. The 
longer the samples are at a lower temperature the better the RNA yield (this is the first 
good stopping point). 
 
 Centrifuge mixture at 12,000xg for 15 min at 4oC. RNA precipitate will form a pellet on 
side and bottom of the tube. 
 
 Remove contaminant “bubble” from beneath pellet (if present) and re-centrifuge at 
12,000xg for 15 min at 4oC (repeat if necessary). Once contaminant “bubble” no longer 
remains, remove and discard supernatant in appropriate ISO waste container. 
 
 Wash RNA pellet by adding at least 1 ml of 75% ethanol per ml of Tri Reagent (use 
100% ethanol and DEPC water to make 75% ethanol). 
 





 Centrifuge at 12,000xg for 5 min at 4oC. Samples can be stored in ethanol at 4oC for 1 
week and up to a year at –20oC. 
 
 Remove and discard supernatant in appropriate EtOH waste container without disturbing 
RNA pellet. 
 
 Dry RNA pellet for 5-10 min (will probably take 15-30 if not more depending on how 
much supernatant is removed) by air-drying or by using a P10 pipetteman to remove any 
remaining ethanol. Do not let RNA pellet dry completely and do not dry under Speed-
vacuum; complete drying greatly decreases RNA solubility.  
 
 Add 20 µL of RNAase-free (DEPC) H2O to RNA pellet, mix well, and quick-spin; store 
at -80 oC. 
 
Nanodrop Spec procedure 
 
 If proceeding directly from RNA isolation, let samples sit on ice for at least 15-20 min. 
Otherwise get out samples from the freezer and thaw on ice (~30 min). 
 
 Vortex and quick-spin samples to ensure sufficient mixing. 
 
 Log onto computer and start Nanodrop software. Select Nucleic Acid. 
 
 Clean both parts of Nanodrop detector with ddiH2O and dry with Chemwipe. 
 
 Add 2 l drop of ddiH2O and click OK to calibrate. 
 
 Change sample type to RNA (software defaults to DNA). 
 
 Add 2 l drop of ddiH2O and click Blank (will automatically give it sample number of 0). 
 
 Change sample ID and add 2 l drop of sample; click Measure. Once complete, open 
detector, clean with ddiH2O and dry. Repeat for remainder of samples. 
 
 Upon analyzing all samples, transfer data file(s) [located in C:/nanodrop 
data/default/(choose folder corresponding to type of data)/] to your computer and import 




 cDNA was synthesized from RNA samples using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, USA) per the manufacturer’s 






Quantitative Real-Time PCR—Collagen I, TGF-β3, PTGS2: 
Gene TaqMan Assay 
18S Hs99999901_s1 
Collagen I Gg03325897_m1 
TGF-β3 Gg03371523_m1 
PTGS2 Gg03320004_m1 
Table 5: TaqMan primer-probes used for qRT-PCR. 
Preparation Steps  
 
 Make plate maps  
 Sign up to use rtPCR machine in Keck Center 
 Make all calculations and label all tubes 
 
 RNA Isolation: follow Tri Reagent protocol 
 cDNA samples should be stored at -20⁰C unless performing rtPCR on same day. 
 PRODUCT = 40 µL cDNA 
 
Dilutions and Master Mixes 
 
Dilute cDNA 1:5 (add 160µL DEPC-H2O per sample, for a total of 200µL) – gives you ~3 plates 
(probably less) 
OR 
Dilute cDNA 1:10 (add 360µL DEPC-H2O per sample, for a total of 400µL) – gives you 5 plates 
worth 
 
 Thaw cDNA on ice (if needed) 
 Dilute cDNA with appropriate amount of DEPC-H2O  
o Quick spin when needed 
 
 Label tubes for each primer/probe MM 
o A 384-well plate has 24 columns and 16 rows. Each column is a different sample, 
so duplicates run vertically; thus, you can fit 8 genes on one plate and 24 different 
samples. We round up to 28 in order to account for volume lost in transfer/when 
using repeater pipettes.   
 
Master Mix (per gene): * Note, this breakdown is for a full plate (24 columns) *  
Taqman = 280µL  
primer/probes = 28µL  






 Vortex then centrifuge Master Mixes 
 Dispense 5.5µL MM for each well using repeater pipette 
 Turn plate and dispense 4.5µL sample (diluted cDNA) into appropriate wells 
 Tap the plate gently to get all volumes to fall to the bottom of the wells 
 Cover plate with pressure-adhesive plate cover and cleanly tear off edges 
PRODUCT = 10µL (cDNA with primer/probe MM) 
 




 Take foil-wrapped 384-well optical plate to Keck Center 
 Remove foil, balance plate in centrifuge (use provided balance plates) 
 Run centrifuge using Program 1 (20,000rpm at 1min) – use instructions on centrifuge 
 In other room, open QuantStudio rtPCR program 
 Click “New Experiment” at the top left 
o Enter all appropriate fields for each of the tabs on the left 
o Create Experiment Name 
o Scan your barcode 
o Create username 
 Default settings for “Experiment Properties” should be fine EXCEPT 
#5 
 QuantStudio 7 
 384-well 
 Comparative CT or Standard Curve 
 TaqMan Reagents 
 Standard (NOT “Fast”!) 
 On “Assign” tab, create your plate map (highlight all occupied wells) 
 On “Run Method” tab, re-adjust reaction volume to 10μL 
 Save the experiment under Nowak folder, under your folder 
 Click “File -> Close” – this will close the experiment but not the 
program 
 NOTE: You HAVE to close the experiment in order to run the next steps 
 Open Automation Controller program 
o Click YES to the serial number prompt and the prompts on the following 
pop-up 
o Once the window opens, click “add plates” at the bottom right 
o Find the experiment that you just saved from QuantStudio (make sure the 
barcodes match) 
o Load your plate into Rack 1 
o Remove any completed plates from Rack 3 
o Click “start batch” to start the PCR machine 
 The robotic arm will go through its own trouble shooting motions, 





it will lower into Rack 1, grab your plate, scan the barcode, and 
load it in the plate rack. MAKE SURE THE ARM DOESN’T 
DISLODGE YOUR PLATE FROM THE PLATE HOLDER! 
 Everything should be running, you can double check the read-out 
on the machine itself and on the computer screen. 
Getting Your Data 
 
 When your run is complete, you can access the file and send it to yourself through 
Box: 
o Open chrome, Box will automatically come up 
o Log in with your UIUC credentials 







 Put 50-100 mg of fibroid tissue into 2 mL of NP-40 lysis buffer. 
 Homogenize with 2mm Tungsten Carbide beads and TissueLysterII (both from 
Qiagen) for 25 seconds followed by 5 seconds on wet ice. 
o Repeat until fibroids are completely dissociated (approx. 2-3 intervals) 
 Centrifuge samples at 12,000xg for 10 min at 4°C. 







 Perform BCA Protein Assay (Pierce™, ThermoFisher, Waltham, MA, USA) to 
determine protein concentration of samples 
 Calculate 3:1 ratios of protein (15 µg) to 4xLSB & mix protein and 4xLSB 
 Denature protein for 5 min at 95°C 
 Load gel into running box & fill with running buffer 
 Load protein diluted in 4xLSB to wells 
 Load 5µL BioRad protein ladder to one well 
 Run gel at 120V for 1 hour 
 Transfer to PVDF membrane: 
o Build sandwich from black to white IN THIS ORDER (be sure sponges and filter 
paper are soaked in transfer buffer): 
 2 sponges 
 Filter paper 
 Gel 
 PVDF membrane 
 Activate in methanol for 30 sec 
 Filter paper 
 2 sponges 
 Insert sandwich into transfer box, add ice pack and stir bar, fill with transfer buffer 
 Run on stir plate at 100V for 1 hour 
 Block membrane in 3% BSA/TBST overnight at 4°C on plate shaker 
 Incubate in primary antibody (COX-2, 1:1000) diluted in 2% BSA/TBST overnight at 
4°C on plate shaker 
 Wash in TBST 3x10 min on plate shaker 
 Incubate in secondary antibody (HRP-Anti-Rabbit, 1:5000) diluted in 2% BSA/TBST for 
1 hour at room temp. on plate shaker 
 Wash in TBST 3x10 min on plate shaker 
 Incubate in chemiluminescence for 5 min in the dark 
 Visualize on ImageQuant machine 
 Place membrane in stripping buffer for 15 min at room temp on plate shaker 
 Block in 3% BSA/TBST overnight at 4°C on plate shaker 
 Incubate in primary antibody (β-actin, 1:1000) diluted in 2% BSA/TBST overnight at 
4°C on plate shaker 
 Wash in TBST 3x10 min on plate shaker 
 Incubate in secondary antibody (HRP-Anti-Rabbit, 1:5000) diluted in 2% BSA/TBST for 
1 hour at room temp. on plate shaker 
 Wash in TBST 3x10 min on plate shaker 
 Incubate in chemiluminescence for 5 min in the dark 
 Visualize on ImageQuant machine 
